New drugs and therapeutic strategies in pharmacoresistant epilepsy by Terrone, Gaetano
0 
 
 
 
“FEDERICO II” 
                   UNIVERSITY OF  NAPLES 
 
 
PhD Program in 
Clinical and Experimental Medicine  
    Curriculum in Human Development and Growth 
XXIX Cycle 
       
Coordinator 
Prof. Gianni Marone 
 
PhD Thesis 
“New drugs and therapeutic strategies 
in pharmacoresistant epilepsy” 
 
 
 
Tutor                                                                      PhD student                                                             
Prof. Ennio Del Giudice                                         Dr. Gaetano Terrone                                                
 
Co-Tutor 
Dr.ssa Annamaria Vezzani 
 
 
 
Academic Year 2016-2017 
 
 
 
 
 
wertyuiopasdfghjklzxcvbnmqw
 
1 
 
INDEX 
 
 
BACKGROUND AND AIMS ........................................................................................................ 4 
Role of inflammation in pathophysiology of epilepsy:                                                              
from bench to the bedside and viceversa ......................................................................................... 4 
References ........................................................................................................................................ 8 
 
CHAPTER I: MECHANISMS OF EPILEPTOGENESIS ........................................................ 11 
1.1 New definition of epileptogenesis ........................................................................................... 11 
1.2 Animal models for studying epileptogenesis and anti-epileptogenic treatments ............... 13 
1.3 Mechanisms of epileptogenesis ............................................................................................... 15 
1.4 The role of the hippocampus in epilepsy and epileptogenesis ............................................. 16 
1.5 Inflammatory mechanisms as potential targets of antiepileptogenic treatments .............. 18 
1.6 Biomarkers of epileptogenesis ................................................................................................ 21 
1.8 References ................................................................................................................................ 22 
1.9 Publications .............................................................................................................................. 27 
 
 
CHAPTER II: STUDY OF A NOVEL COMBINATION OF DRUGS WITH 
ANTIOXIDANT EFFECTS IN AN EXPERIMENTAL MODEL OF ACQUIRED 
EPILEPTOGENESIS ................................................................................................................... 32 
2.1 Introduction ............................................................................................................................. 32 
2.1.1 Oxidative stress ................................................................................................................... 32 
2.1.2 Oxidative stress and Central Nervous System (CNS) ........................................................ 33 
2.1.3 Oxidative stress and epilepsy: experimental and clinical evidence .................................... 34 
2.1.4 High Mobility Group Box-1 (HMGB1) ............................................................................. 35 
2.1.5 HMGB1 and neuronal hyperexcitability ............................................................................ 37 
2.1.6 HMGB1 isoforms ............................................................................................................... 38 
2.2 Aims of study ........................................................................................................................... 41 
2.3 Materials and methods ............................................................................................................ 42 
2.3.1 Animals ............................................................................................................................... 42 
2.3.2 Electrical status epilepticus ................................................................................................. 42 
2.3.3 Spontaneous seizures detection and quantification ............................................................ 43 
2.3.5 In vivo study design ............................................................................................................ 45 
2.3.6 Blood collection .................................................................................................................. 46 
2.3.7 Rat brain histology and immunohistochemistry ................................................................. 46 
2 
 
2.3.8 Human subjects ................................................................................................................... 50 
2.3.9 Immunohistochemistry in human brain .............................................................................. 51 
2.3.10 Analysis of HMGB1 isoforms by electrospray ionization liquid chromatography mass 
spectrometry ................................................................................................................................ 52 
2.3.11 HPLC analysis of GSH, GSSG, GS-Pro ........................................................................... 53 
2.3.12 Behavioral test .................................................................................................................. 54 
2.3.13 Cortical cell cultures ......................................................................................................... 54 
2.3.14 Imaging of intracellular Ca
2+
 ([Ca
2+
]c) and mitochondrial membrane potential (Δψm) ... 55 
2.3.15 Statistical analysis ............................................................................................................. 56 
2.4 Results ...................................................................................................................................... 58 
2.4.1 Assessment of oxidative stress during epileptogenesis ...................................................... 58 
2.4.2 Anti-oxidant drug combination vs single treatment ........................................................... 58 
2.4.3 Therapeutic effects of antioxidant drug combination in SE-exposed rats .......................... 60 
2.4.4 Spontaneous seizures onset and their progression .............................................................. 60 
2.4.5 Cognitive deficits ................................................................................................................ 61 
2.4.6 Neurodegeneration .............................................................................................................. 61 
2.4.7 Effects of the anti-oxidant drug combination on the redox state of HMGB1 ..................... 62 
2.4.8 Oxidative stress in brain specimens from patients with status epilepticus and in temporal 
lobe epilepsy ................................................................................................................................ 63 
2.5 Discussion ................................................................................................................................. 64 
2.6 Figures and legends ................................................................................................................. 69 
2.7 References ................................................................................................................................ 90 
2.8 Publication ....................................................................... Errore. Il segnalibro non è definito. 
 
 
 
 
CHAPTER III: NEW THERAPEUTIC STRATEGIES IN A MICE MODEL OF 
REFRACTORY STATUS EPILEPTICUS ............................................................................... 101 
3.1 Introduction ........................................................................................................................... 101 
3.1.1 Status Epilepticus: definition and classification ............................................................... 101 
3.1.2 Treatment and Prognosis: ................................................................................................. 103 
3.1.3 Role of MAGL pathway in epilepsy: ................................................................................ 105 
3.1.4 Role of ketogenic diet in epilepsy .................................................................................... 106 
3.2 Aims of study ......................................................................................................................... 108 
3.3 Materials and methods .................................................... Errore. Il segnalibro non è definito. 
3.3.1 Animals ....................................................................... Errore. Il segnalibro non è definito. 
3 
 
3.3.2 Drug Formulation, Dosing and Tissue Collection ...... Errore. Il segnalibro non è definito. 
3.3.3 Pharmacokinetic Measurement ................................... Errore. Il segnalibro non è definito. 
3.3.4 Pharmacodynamic Measurement ................................ Errore. Il segnalibro non è definito. 
3.3.5 Mouse model of status epilepticus .................................................................................... 112 
3.3.6 CPD-4645 treatment ......................................................................................................... 113 
3.3.7 Novel object recognition test (NORT).............................................................................. 114 
3.3.8 Fluoro-Jade staining.......................................................................................................... 115 
3.3.9 Real-time quantitative polymerase chain reaction analysis .............................................. 116 
3.3.10 β-hydroxybutyrate measurement in plasma .................................................................... 116 
3.3.11 Randomization and statistical analysis of data ............................................................... 116 
3.4 Results .............................................................................. Errore. Il segnalibro non è definito. 
3.4.1 Pharmacokinetic and pharmacodynamic analysis of CPD-4645Errore. Il segnalibro non è 
definito. 
3.4.2 Effect of CPD-4645 on status epilepticus and the associated cognitive deficit in standard 
diet (SD)-fed mice ..................................................................................................................... 118 
3.4.3 Effect of CPD-4645 on status epilepticus in Cnr1
-
/
- 
and related
 
Wt mice and survival 
curves ......................................................................................................................................... 119 
3.4.4 MAGL inhibition attenuates neuroinflammation following SE ....................................... 120 
3.4.5 Effect of CPD-4645 on status epilepticus in ketogenic diet (KD)-fed mice ..................... 120 
3.4.6 Effect of CPD-46454 on neuronal cell loss ...................................................................... 120 
3.5 Discussion ............................................................................................................................... 122 
3.6 Figure and legends ................................................................................................................ 126 
3.7 References .............................................................................................................................. 128 
 
CONCLUSIVE REMARKS ....................................................................................................... 138 
 
CURRICULUM VITAE ............................................................................................................. 140 
 
 
 
 
 
4 
 
BACKGROUND AND AIMS 
 
Epilepsy is a brain disorder characterized by an enduring predisposition to generate 
recurrent epileptic seizures and by the neurobiologic, cognitive, psychological and social 
consequences of this condition [1].  
This disorder affects over 50 million people worldwide and is characterized by significant 
co-morbidities, unique stigmatization of affected individuals, and high societal cost.  
Current antiepileptic drugs provide symptomatic relief from seizures, have multiple 
adverse effects, and fail to control seizures in up to 30% of people [2]. This represents a 
major unmet clinical need. New anti-seizure treatments for epilepsy are unlikely to bridge 
this treatment gap. The next generation of drugs should potentially be able to delay or 
prevent the onset of epilepsy in susceptible individuals (anti-epileptogenesis) or to halt or 
reverse its progression and/or improve the neuropathology and the associated 
comorbidities (disease-modifying) [3]. In order to develop such drugs, there is the need to 
understand the pathological processes occurring in the brain of people exposed to 
epileptogenic injuries, or with an established diagnosis of epilepsy. 
 
Role of inflammation in pathophysiology of epilepsy: from bench to the bedside and 
viceversa 
Clinical and experimental evidence provided strong support to the hypothesis that 
inflammatory processes are involved in the pathophysiology of epilepsy [4–7]. In the 
clinical setting, the first evidence of the potential role of inflammation in human epilepsy 
were derived from the use of steroids and other anti-inflammatory treatments as 
anticonvulsant agents in some drug-resistant epilepsies [8,9]. Moreover, chronic brain 
inflammation, involving activated microglia, astrocytes, endothelial cells of the blood–
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brain barrier, peripheral immune cells, and the concomitant production of inflammatory 
mediators—was observed in patients with Rasmussen encephalitis [10]. 
Other evidence of the involvement of immune and inflammatory mechanisms in epilepsy 
came from the high incidence of seizures in autoimmune diseases, and the discovery of 
limbic encephalitis as a cause of epilepsy [11,12]. 
Inflammatory mediators have also been implicated as contributors to the onset of febrile 
seizures (FS) and to the progression from FS, in particular prolonged, to epilepsy, 
influencing the process of epileptogenesis [13].  
Several inflammatory mediators have also been detected in surgically resected brain tissue 
from patients with temporal lobe epilepsy (TLE) and cortical dysplasia-related epilepsy 
[4,7]. The finding that brain inflammation occurred in epilepsies not classically linked to 
immunological dysfunction highlighted the possibility that chronic inflammation might be 
intrinsic to some epilepsies, irrespective of the initial insult or cause, rather than being 
only a consequence of a specific underlying inflammatory or autoimmune etiology. 
The mounting evidence for a role for inflammatory processes in human epilepsy has led to 
the use of experimental rodent models to identify putative triggers of brain inflammation 
in epilepsy, and to provide mechanistic insights into the causal links between 
inflammation and seizures [4,6,14]. 
Experimental studies have shown that epileptogenic brain injuries (i.e. status epilepticus, 
prolonged febrile seizures) can trigger the release of several inflammatory mediators such 
as cytokines (i.e. interleukin-1β or TNF-α) and “danger signal molecule” (i.e. high-
mobility-group box 1) in brain regions, involved in the generation and propagation of 
epileptic activity [15-17]. These molecules have shown to provide proconvulsant activity 
and to have a crucial role in the epileptogenesis in various seizure models [15-17]. 
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Notably, the finding that inflammatory events persist during epileptogenesis in 
experimental models, thus outlasting the initial precipitating event, suggests that 
inflammatory processes may precede the onset of epilepsy in humans, possibly playing an 
etiopathogenetic role in the occurrence of spontaneous seizures. 
Therefore, an essential and crucial question is whether targeting inflammatory molecules 
and pathways may result in anti-ictogenesis, anti-epileptogenesis and/or disease-
modification effects. Therefore, preclinical testing in models mimicking relevant aspects 
of epileptogenesis are needed to guide integrated experimental and clinical trial design.  
Moreover, experimental models are also needed to study the mechanisms ensuing in the 
brain during prolonged seizures and status epilepticus (SE). Experimental evidence 
highlighted that inflammation may play a key role in brain during SE and its pathological 
long-term consequences [18-21]. SE is a life-threatening condition, operationally defined 
as ongoing seizures, or repetitive seizures without recovery of baseline clinical conditions 
in between, lasting for at least 5 min [22].  
Also in the therapeutic management of SE, there is an urgent need of novel therapies 
considering that about one-third of patients with SE still continue seizing despite the first 
two treatment lines, evolving to refractory SE, and half of these subsequently develop 
super-refractory SE.  
Therefore, the focus of my research was on preclinical characterization and development 
of novel antiepileptic and disease-modifying treatments in animal models of epilepsy or 
SE, with a high translational potential for clinical applications. 
In particular, my PhD program has been focused on the study of the following lines of 
research: 
-study of the epileptogenic mechanisms in experimental models of epilepsy;  
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-study of new anti-epileptogenic and disease-modifying drugs targeting oxidative 
stress in a rat model of acquired epilepsy induced by electrical status epilepticus 
(SE); 
 
-study of new therapeutic strategies in an experimental model of benzodiazepine-
refractory status epilepticus.  
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CHAPTER I 
“MECHANISMS OF EPILEPTOGENESIS” 
 
1.1 New definition of epileptogenesis 
Epileptogenesis is characterized by the development and extension of brain tissue capable 
of generating spontaneous seizures, thus resulting in the development of an epileptic 
condition and/or progression of the epilepsy after it is established [1]. Epileptogenesis can 
be triggered by congenital, genetic or acquired insults, e.g. neurotrauma, stroke, 
infections, status epilepticus. The current definition takes into consideration the new 
knowledge related to the cellular, molecular and functional changes occurring in seizure-
prone brain areas both before and during the development of epilepsy, as emerging from 
clinical [2] and basic science investigations in animal models [3-5]. Consequently, the 
concepts related to epileptogenesis have evolved significantly over the past few years. The 
complexity of this process has been acknowledged as well as the evidence that 
epileptogenesis is not a stepwise process rather a continuum of modifications [6]. 
Moreover, epileptogenesis is not merely limited to the prodromal phase preceding the 
onset of spontaneous seizures, but also underlies the development of the disease after its 
diagnosis [1]. This novel view is compatible with clinical evidence reporting that human 
epilepsy has a progressive course in a significant percent of cases [2]. This concept is not 
only mechanistically but also therapeutically relevant since it means that epileptogenesis 
can potentially be targeted also after spontaneous seizures arise. In accord, anti-
epileptogenic interventions could be designed not only for preventing the onset of the 
disease but also for providing seizure modification (i.e. less frequent or shorter seizures, 
milder seizure type, change from drug-resistant to drug-responsive) and improving the 
related pathological outcomes (disease-modifying treatments). Another relevant aspect 
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emerging from basic science investigations relates to comorbidities such as anxiety, 
cognitive deficits and depression, that are often associated with epilepsy [7,8]. There is 
intense research to understand the mechanisms leading to comorbidities giving insights 
that they may share common molecular events with the hyperexcitability phenomena 
underlying seizure generation. Notably, animal models clearly show that these comorbid 
behaviors often arise before the development of spontaneous seizures indicating that they 
are not a mere consequence of seizures or the anticonvulsive treatments [9-16]. 
A consensus definition of epileptogenesis is crucial for designing therapeutic interventions 
based on specific targets and for searching mechanistic biomarkers of this process that are 
still lacking. In fact, the development of effective therapies to prevent or treat 
epileptogenesis remains an urgent unmet clinical need. Clinical trial designs for novel 
therapeutics able to prevent (anti-epileptogenic) or favorably change the disease course 
(disease-modifying) are likely to hinge on discovering non-invasive biomarkers that allow 
early identification of patients at high risk of developing the disorder, as well as patients 
with a progressive course of the disease, including the development of comorbidities and 
pharmacoresistance [17]. Both aspects are challenging and rely upon a better 
understanding of the mechanisms of epileptogenesis and their dynamics during disease 
development (Figure 1). 
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Figure 1. Mechanisms of treatment during epileptogenesis (from Terrone et al, 2016) 
 
1.2 Animal models for studying epileptogenesis and anti-epileptogenic treatments 
Animal models of pediatric and adult epilepsies have allowed to study the molecular 
mechanisms contributing to the complex process of epileptogenesis. The choice of 
adequate animal models is essential in order to test new treatments capable of preventing 
or modifying epilepsy after epileptogenic brain injuries. The most widely used models in 
this respect are kindling, post-SE models of TLE, and models of traumatic brain injury 
(TBI) [18-20]. In particular, we mainly studied new anti-epileptogenic treatments in two 
models of TLE obtained by either continuous electrical stimulation of hippocampus in 
adult male rat or intra-amygdala kainic acid injection in adult male mice.  
In the first model, the CA3 area of ventral hippocampus is electrically stimulated 
unilaterally [21-23] until the develop of a convulsive self-sustained limbic status 
epilepticus (SSLSE). The following criteria allow the identification of rats experiencing 
SE and subsequently developing epilepsy: (i) an EEG pattern of uninterrupted bilateral 
spikes in the hippocampi in the absence of electrical stimulation (i.e. the “stimulus-off” 
period); -(ii) development of convulsive SE for 60 min during electrical stimulation;  (iii) 
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development of self-sustained convulsive SE for at least 4 h after termination of electrical 
stimulation. SE remits spontaneously within 24 h from the initial stimulation. It may be 
not necessary to interfere pharmacologically to stop SE, since no mortality is observed in 
this model.  
In this model, 100% of the animals conforming to the criteria reported above develop  
electroencephalographic and behavioral spontaneous recurrent seizures (SRS), leading to a 
diagnosis of epilepsy [24].  
The prodromal phase of epileptogenesis lasts about 2 weeks on average; in fact, the onset 
of the first spontaneous seizure occurs about 14 ± 3 days after the induction of SE [23]. 
About 80% of epileptic rats develop an increase in SRS frequency during 5 months from 
epilepsy onset, while no progression in SRS is observed in the remaining 20% of epileptic 
rats. In the second model, the kainic acid is injected into the basolateral nucleus of the 
amygdala in adult male mice, leading to SE, lasting about 7 hours on average. After 40 
minutes from SE onset, mice received diazepam intraperitoneally to improve their survival 
rate. The development of spontaneous recurrent seizures occurs after a seizure-free latent 
period of about 5 days [25]. In addition to these models in which brain injury is induced 
by SE, antiepileptogenic drug effects can also be studied in genetic animal models of 
epilepsy and in neonatal models. 
However, none of the models used in the search for antiepileptogenic drugs has been 
validated as yet. In fact, one of the major challenges is represented by the validation of the 
anti-epileptogenic or disease modifying treatments identified in a specific animal model in 
an appropriately designed clinical trial.  
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Figure 2.  Experimental model of post-SE TLE in adult male rats 
 
1.3 Mechanisms of epileptogenesis  
Experimental data suggest that changes in specific molecules and cell signaling pathways 
after the inciting epileptogenic event show a specific temporal profile of induction, 
persistence and recovery. Many of these alterations continue to occur after the onset of the 
first spontaneous seizure and have been validated in human epileptic foci surgically 
resected from patients affected by various forms of drug-resistant epilepsy. 
Pharmacological or genetic interventions targeting such molecules and pathways can 
affect the onset and/or the development and severity of the ensuing epilepsy thus 
demonstrating their role in the process of epileptogenesis. The most studied and better 
validated molecules implicated in epileptogenesis include those related to immunity and 
inflammation [e.g. cytokines and danger signals such as interleukin-1 beta (IL-1), high 
mobility group box 1 (HMGB1), cyclooxygenase-2 (Cox-2) and prostaglandins, 
complement system], trasforming growth factor-beta receptor (TGF-) signaling activated 
by albumin in astrocytes following alterations in the blood brain barrier (BBB) 
permeability, extracellular matrix proteins, adenosine kinase, mTOR pathway (TSC1 and 
TSC2 gene), neurotrophic kinase receptors such as TrkB receptors activated by BDNF, 
JAK/STAT signaling pathways, and a variety of acquired and congenital channalopathies 
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and epigenetic factors. Functional interaction may exist among these molecular pathways 
suggesting that discovery of nodal points of intersection may facilitate the development of 
drugs controlling the broad cascade of pathologic events taking place during 
epileptogenesis [3-5]. 
This list of potential mechanisms underscores the importance of non neuronal cells such as 
astrocytes, microglia, and endothelial cells of the BBB, as key contributors to neuronal 
network dysfunctions leading to seizures and comorbidities [26-27]. Additionally, these 
molecules represent potential targets for anti-epileptogenesis interventions and potential 
sources of mechanistic biomarkers of epileptogenesis. 
 
1.4 The role of the hippocampus in epilepsy and epileptogenesis 
Most of current assumptions of neuronal mechanisms of epileptogenesis come from the 
epileptogenic changes that occur in the sclerotic hippocampus, created in animals and 
reported in patients with TLE [28].  
Thus, even if other models of epilepsy, in particular genetic or post-TBI epilepsies, 
provided the proof that epileptogenic process is not confined to hippocampus, this region 
remains one of the most important brain area involved in the neuronal hyperexcitability 
underlying the seizures. Hippocampal region is located in the temporal lobe and consists 
of the hippocampal formation, which includes Ammon’s horn (CA), dentate gyrus and 
subiculum, and parahippocampal region. The hippocampus receives informations from 
many associative neocortical areas. These informations come to hippocampus through 
structures of parahippocampal region, in particular the perirhinal cortex and 
parahippocampal cortex, which themselves project to the entorhinal cortex. After being 
processed in the hippocampus, these informations are relayed, via the entorhinal cortex to 
neocortical areas. Therefore, the entorhinal cortex represents the main input and output 
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way to the hippocampus. The hippocampus is divided into four sub-fields CA1, CA2, 
CA3, CA4 -according to density, size and branching of axons and dendrites of pyramidal 
cells-, and dentate gyrus. Hippocampus has a three-layered structure in contrast to six 
layers of neocortex, consisting of a molecular layer), cellular or pyramidal layer and 
polymorphic layer. The dominant neurons in the hippocampus are the pyramidal cells. 
The different regions of hippocampus are interconnected through a tri-synaptic circuit, 
consisting of three defined synaptic relay stations (Figure 4). 
        
 
Figure 4. Hippocampal tri-synaptic circuit (Deng et al, 2010) 
The information from the entorhinal cortex enters the hippocampus through the axons 
forming the “perforant pathway". The fibers of the performant pathway form excitatory 
synapses on the granular cells of the dentate gyrus. The axons of dentate granule cells 
("mossy fibers") innervate CA3 pyramidal cells. CA3 neurons synapse onto CA1 
pyramidal cells via the "Schaffer collateral pathway”. The output of CA1 goes to and from 
subiculum and, finally, back to the entorhinal cortex. The unidirectional flow of this 
circuit is broken only by the occasional synapses between the apical dendrites of CA3 and 
CA1 neurons, and fibers of the perforant pathway. The main neurotransmitter of the 
hippocampal formation is the glutamate, and the massive presence of excitatory synapses 
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explains the vulnerability of this brain area to seizures.  In addition to glutamate, the 
inhibitory neurotransmitter acid-γ-aminobutyric acid (GABA) plays a pivotal role in the 
dentate gyrus, controlling the activities of the main excitatory cells. Several studies 
demonstrated the co-localization of the GABA with different calcium-binding proteins, 
such as parvalbumin (PV), calretinin (CR) and somatostatin (SST). In particular, the hilum 
of the dentate gyrus is characterized by the presence of three populations of inhibitory 
interneurons: the subgranular basketcells (parvalbumin-positive), the cells of the 
polymorphic layer (somatostatin-positive) and the mossy cells (calretinin-positive), 
GABAergic interneurons which establish numerous synaptic contacts axon-dendritic and 
dendro-dendritic with other inhibitory interneurons, which in turn communicate with 
excitatory cells of the granule layer [29].  The excitation level of granule cells is critical to 
determine the excitability of the hippocampus, and consequently of the limbic system. The 
degeneration of specific populations of hilar interneurons of the dentate gyrus that control 
the excitability of granule cells, and subsequent molecular, synaptic and cellular 
modifications, appear to significantly contribute to the development of epilepsy in 
experimental models. A wide range of molecular changes also independent of neuronal 
damage are involved in the epileptogenesis [30]. 
It still remains to be clarified which are the molecular and biochemical mechanisms 
necessary for the establishment of a neuronal hyperexcitability substrate and which is the 
cascade of events triggered by a epileptogenic event that is relevant to the generation and 
occurrence of spontaneous seizures. 
 
1.5 Inflammatory mechanisms as potential targets of antiepileptogenic treatments 
Whether different etiological factors induce distinct or overlapping epileptogenic 
mechanisms remains unknown, however, the search for such pathogenic mechanisms in 
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animal models has shown that neuroinflammation in seizure-prone brain regions is a 
common feature of various forms of drug-resistant symptomatic epilepsies in humans and 
animal models [31, 32]. Neuroinflammation is determined by the synthesis and release of 
pro-inflammatory molecules with neuromodulatory properties by glia, neurons and the 
BBB endothelium, in the context of innate immunity activation. De novo status epilepticus 
and other potential epileptogenic injuries (e.g. neurotrauma, stroke, CNS infections, gene 
mutations, i.e., GAERS rats with spike-and-waive discharges [33] or cystatin B mutation 
in a model of progressive myoclonus epilepsy [34]) trigger neuroinflammation, which 
therefore represents a consistent feature of epileptogenesis irrespective of the initial insult. 
Which are the triggering factors of neuroinflammation during epileptogenesis, and 
whether common factors ignite inflammation following differing epileptogenic injuries are 
still open questions. Basic knowledge of the mechanisms of inflammation by innate 
immunity activation, and experimental findings in models of seizures and epileptogenesis, 
suggest that one pivotal generator of neuroinflammation in epileptogenesis is likely to be 
the activation of toll-like receptors (TLR) by endogenous ligands, namely the 
alarmins/danger signals [35, 36]. 
These are endogenous molecules constitutively available that are released by brain cells 
and leukocytes upon tissue injury. One of such molecules is High Mobility group Box 1 
(HMGB1) which is released by various epileptogenic injuries and is induced in human 
brain tissue from various forms of pharmacoresistant epilepsy [35, 36]. The activation and 
assembly of the inflammasome, a multiprotein complex which includes the cysteine 
protease ICE/caspase-1, is required for the biosynthesis and release of both the 
biologically active form of IL-1β and HMGB1. Extracellular ATP-mediated stimulation of 
P2X7 receptors and reactive oxygen species are powerful inducers of ICE/Caspase-1, and 
they are both commonly produced during epileptogenesis [35, 36]. 
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Notably, it is well established that neuroinflammatory molecules such as IL-1beta, TNF-
alpha, PGE2 and the complement system contribute to ictogenesis by promoting neuronal 
network hyperexcitability via activation of specific transcriptional and post-translational 
molecular mechanisms in neurons and glia, thereby reducing seizure threshold and 
promoting seizure generation and recurrence [35, 36]. In accord, anti-inflammatory 
treatments are anticonvulsive in some human pediatric and adult epilepsies [31, 37], and 
specific anti-inflammatory drugs significantly reduce acute symptomatic seizures and 
chronic spontaneous seizures in animal models of existing epilepsy [31, 37]. Additionally, 
target-specific anti-inflammatory treatments in SE models are providing increasing 
evidence of anti-epileptogenic and neuroprotective effects, thus supporting that 
neuroinflammation is also implicated in epileptogenesis [38, 39]. In general, anti-
inflammatory drugs transiently given after the epileptogenic insult are unable to prevent 
the onset of epilepsy but significantly improve pathological outcomes. Typically, the 
frequency and severity of spontaneous seizures are significantly reduced, and in several 
instances anti-inflammatory drugs afford neuroprotection by decreasing the number of 
degenerating neurons, and comorbidities are often improved, in particular cognitive 
deficits. Interestingly, anti-inflammatory drug combinations showed improved therapeutic 
value as compared to drugs given alone [37]. This evidence suggests that the complex and 
reverberant inflammatory cascade activated during epileptogenesis may require a 
concomitant blockade of independent pathways for efficient interference with 
epileptogenesis. A few therapeutic attempts have been developed so far early after the 
onset of spontaneous seizures [40] providing proof-of-concept evidence that a delayed 
anti-inflammatory intervention may improve the disease prognosis.  
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1.6 Biomarkers of epileptogenesis 
A biomarker for epileptogenesis is an objectively measurable characteristic of a biological 
process that reliably identifies the development, presence, severity, progression, or 
localization of an epileptogenic abnormality [1,17]. The validation of non-invasive, and 
easy to measure, biomarkers would be of great utility to monitor epileptogenesis, thus 
facilitating the screening of potential antiepileptogenic treatments in animal models. 
Moreover, such biomarkers, particularly if measurable in blood or body fluids, may allow 
the stratification of patients at high risk of developing epilepsy after a potential 
epileptogenic injury thereby enriching the patient population eligible for clinical trials and 
making such trials affordable. 
Research on basic mechanisms of epileptogenesis in animal models has provided a list of 
potential biomarkers ranging from those derived from genetic analyses to circulating, 
imaging (MRI, PET), electrophysiological or behavioral biomarkers  [16, 17]. 
Biomarker discovery would strongly support the initiation of future clinical trials, and 
together with testing potential novel drugs would provide a major advance in the treatment 
of human epilepsy [41] 
 
1.7 Conclusion 
The development of new drugs preventing epilepsy and improving its prognosis requires a 
deep understanding of pathogenic mechanisms underlying the disease. Importantly, 
considering the complex pathophysiological underpinnings of the epileptogenesis, it is 
likely necessary to interfere with this process at multiple levels and in various cell types. 
However, neuroinflammation demonstrated to have a pivotal role in seizure pathogenesis 
and so therapeutic approaches targeting inflammatory mechanisms could represent novel 
strategies for drug development in epilepsy.  
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CHAPTER II 
“STUDY OF A NOVEL COMBINATION OF DRUGS WITH ANTIOXIDANT 
EFFECTS IN AN EXPERIMENTAL MODEL OF ACQUIRED 
EPILEPTOGENESIS” 
 
2.1 INTRODUCTION  
2.1.1 Oxidative stress 
Oxidative stress is a pathological condition caused by impaired balance between the 
production of reactive oxygen and nitrogen species (ROS, RNS) and antioxidant defense 
systems promoting their elimination. 
Disruption of this balance may occur following: an overproduction of ROS and RNS, 
decreased functionality of the anti-oxidant systems in the cells or a combination of these 
two factors (Fig.1) [1,2] Experimental evidence demonstrated that free radicals have a 
dual function: at low concentrations, they have important physiological functions (i.e.  
regulation of the vascular tone and erythropoietin production, control of oxygen tension, 
homeostatic maintenance of the redox state tissue, defense against pathogens), whereas at 
high concentrations they induce tissue damage and dysfunction [3].  
There are endogenous anti-oxidant systems that can counteract the increased production of 
ROS and RNS. However, following an excessive production of free radicals, these defense 
mechanisms are insufficient, resulting in the development of oxidative stress. 
Since free radicals have an unpaired electron, they are very unstable and highly reactive 
molecules. Therefore, they react with other substrates such as nucleic acids (nuclear and 
mitochondrial), lipids, proteins and carbohydrates, causing their oxidation, with 
consequent alteration / loss of their function [4]. 
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Figure 1.  Schematic representation of oxidative stress (from Scandalios et al, 2002) 
 
2.1.2 Oxidative stress and Central Nervous System (CNS) 
The brain is particularly susceptible to the harmful effects of free radicals, because: 
• it is characterized by a high aerobic metabolism; the high consumption of oxygen (about 
20% oxygen inhaled) required to fulfill the energy request of neurons, increases the 
production of free radicals [5]; 
• the levels of the anti-oxidant enzymatic (catalase and glutathione peroxidase) and non-
enzymatic (reduced glutathione and vitamin E) systems in neurons are relatively low; 
therefore, these cells are more vulnerable to the action of free radicals [6]; 
• brain contains a high number of mitochondria, required to support the high aerobic 
metabolism. Mitochondrial DNA is particularly exposed to the harmful action of free 
radicals since it is not protected by histones and is localized close to the inner 
mitochondrial membrane, where the free radicals are produced [7]; 
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• brain has a high concentration of polyunsaturated fatty acids contained in the cell 
membrane phospholipids. These molecules are particularly susceptible to peroxidation 
[4,8]. 
 
2.1.3 Oxidative stress and epilepsy: experimental and clinical evidence 
Oxidative stress has been implicated in the pathogenesis of various neurodegenerative 
diseases and epilepsy [8-12]. 
Clinical studies in brain tissue and plasma of patients with temporal lobe epilepsy detected 
the presence of oxidative stress, characterized by morphological alterations of the 
mitochondria [13], increase in lipid peroxidation [14-15],  increase of some anti-oxidant 
enzymes (superoxide dismutase and catalase) [15,16], and reduced concentrations of 
vitamin C and A (two anti-oxidant molecules) [14]. 
Data supporting the involvement of oxidative stress in epilepsy derived from experimental 
models. In particular, biochemical studies conducted in the hippocampus of rats and mice 
exposed to epileptogenic injury (status epilepticus, cerebral trauma, viral infections, 
hypoxia and cerebral ischemia) revealed higher levels of ROS and RNS, oxidized lipids 
and proteins, hydrogen peroxide, and presence of mitochondrial dysfunction 
(ultrastructural changes and DNA damage) [8-9, 17-19]. 
The most important anti-oxidant system is represented by the non-enzymatic reduced 
glutathione (GSH). In presence of oxidative stress, GSH is oxidized in its disulfide form 
(GSSG). The increase in the GSSG/GSH ratio is commonly used as a marker of oxidative 
stress. In rats exposed to status epilepticus it was observed an increase in the GSSG/GSH 
ratio in hippocampal mitochondria [12,19]. These changes occur within 24-48 hours after 
the onset of status epilepticus and persist during epileptogenesis and in the chronic phase 
of epilepsy [12,19]. These evidences indicate that oxidative stress is an active process in 
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the stages preceding the development of spontaneous seizures and thus, it could contribute 
to epileptogenesis. 
The treatment with anti-oxidant agents (such as vitamin C and E, and coenzyme Q10), 
reduces in rats neurodegeneration associated with status epilepticus [20,21], indicating a 
role of the oxidative stress in neuronal death associated to seizures. 
Moreover, oxidative stress may contribute to neuronal damage and onset of 
hyperexcitability phenomena through the modification of the redox state of specific 
proteins due to increased production of free radicals. For example, ROS can increase the 
extracellular concentration of glutamic acid, an excitatory neurotransmitter that 
contributes to the genesis of seizures, through two mechanisms: promoting the 
inactivation of glutamine synthetase, an enzyme that converts glutamic acid into 
glutamine [5]; reducing the activity of GLT-1 and GLAST, two transporters of glutamic 
acid. These transporters remove glutamic acid from the synapses, preventing its 
extracellular accumulation [22]. Finally, High Mobility Group Box-1 is a nuclear protein 
that contributes to seizure recurrence and precipitation only when it is oxidized in the 
extracellular space [23]. 
 
2.1.4 High Mobility Group Box-1 (HMGB1) 
HMGB1 has emerged as one of the main mediators in both acute and chronic 
inflammation and play a key role in seizure mechanisms.  
HMGB1 is a ubiquitous nuclear protein of 216 amino acid, highly conserved among 
mammals (100% homology to the rat-men, 98% mouse-man) and belongs to the group of 
the Damage Associated Molecular Patterns (DAMPS) molecules that alerts nearby cells 
and the immune system to immediate danger, triggering inflammation [24,25]. 
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HMGB1 contains two HMG DNA-binding domains, called A and B boxes, (Fig.2), and an 
acidic tail comprising exclusively glutamic and aspartic acids [26]. 
A and B boxes have two nuclear localization sites (NLSs) directing the traslocation of the 
protein into the nucleus and are organized into -helix structures with a high affinity for 
the non-specific DNA minor groove. Thus, HMGB1 promotes conformational alterations 
of chromatin facilitating gene transcription [24,28]. 
 
 
 
Figure 2. HMGB1 structure (from Antoine et al, 2014) 
 
HMGB1 can exit the cell through two different pathways: passive or active release. In 
central nervous system, HMGB1 is actively secreted by monocytes/macrophages and 
neuronal and glial cells in response to Pathogen-Associated Molecular Patterns (PAMPs) 
or pro-inflammatory cytokines such as IL-1β, TNF-α or lipopolysaccharide (LPS, a 
component of the Gram negative bacterial wall) or passively released by necrotic cells that 
lost their membrane integrity [28,29]. Following its release, HMGB1 acts as a pro-
inflammatory molecule, and assumes pleiotropic functions including the recruitment of 
inflammatory cells into the site of damage, cell mitosis to compensate the loss of necrotic 
cells, the promotion of angiogenesis, the production of cytokines and the activation of 
metalloproteases by contributing to the degradation of the extracellular matrix [27,28]. 
The acetylation of NLS lysines is crucial for nucleus-to-cytoplasm translocation of 
HMGB1, reducing the affinity of this molecule for DNA [24,25].  
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The nucleus-to-cytoplasm translocation of HMGB1 is a necessary condition for its 
subsequent release.  
HMGB1 exerts its effects by interacting with Toll-like receptors (TLR), in particular 
TLR4, RAGE (Receptor for Advanced Glycation End products) and the chemokine 
receptor CXCR4 [30,31].  
TLRs are a family of pattern-recognition receptors with well-established roles in the host’s 
immune response to infection. RAGE behaves as a pattern recognition receptor involved 
in the recognition of endogenous molecules, such as advanced glycation end products 
(AGEs) or S100 proteins, released in the context of infection, physiological stress or 
chronic inflammation [32,33].  
 
2.1.5 HMGB1 and neuronal hyperexcitability 
HMGB1 is released by neurons and glia following a pro-convulsive stimulation [34]. In 
particular, in experimental models of seizures, it has been observed an increase of the 
levels of HMGB1 in the cytoplasm of astrocytes and microglia, indicating that the 
stimulus induced by pro-convulsant agents causes the translocation of HMGB1 from the 
nucleus to the cytoplasm, and consequently its extracellular release [34]. 
HMGB1, administered before the pro-convulsant agents, anticipates the onset of seizures 
and increases the number of seizures and the time spent in seizures, while drugs that 
antagonize the effects (Boxa), or antagonists of the TLR4 receptor (LPS-RS, Cyp), 
drastically reduce seizure activity [34], indicating a contribution of HMGB1-TLR4 axis in 
the mechanisms of seizure precipitation and recurrence. In addition to TLR4 receptors, 
RAGE is involved in the ictogenesis mediated by HMGB1, and the activation of both 
these receptors contributes to the development of spontaneous epileptic activity following 
the induction of status epilepticus [35].  
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However, RAGE and TLR4 play distinct roles in mediating the neuropathological 
processes (neuronal damage and neurogenesis) developing during epileptogenesis [35]. 
These findings suggest that HMGB1 produced after an epileptogenic insult could 
contribute to the seizure precipitation and recurrence. 
The relevance of preclinical data for human epilepsy is supported by evidence that the 
"pattern" of HMGB1 expression described in experimental models has also been observed 
in epileptic tissue of patients with drug-resistant epilepsy (temporal lobe epilepsy and 
epilepsy associated with malformations of cortical development) [34,36,37].  
 
2.1.6 HMGB1 isoforms 
Experimental evidence demonstrated that the redox state of HMGB1 is crucial for the 
interaction with its receptors and for its biological effects [38-40]. In particular, the redox 
state of the three cysteines modulates the extracellular activities of HMGB1. 
HMGB1 contains three cysteines: C23, C45 and C106 according to their position in the 
amino acid sequence of the molecule. The use of mass spectrometry allowed to identify 
three isoforms of HMGB1: disulfide HMGB1, reduced HMGB1 and sulfonyl-HMGB1.  
The cysteines C23 and C45, contained in BoxA domain, can be oxidized to form a 
disulfide bridge [41]. In these conditions the cysteine C106, which is contained in BoxB 
domain, remains unpaired and contributes to bind the TLR4 [31]. This isoform is defined 
disulfide HMGB1 and has pro-inflammatory properties, promoting the production and 
release of cytokines by immunocompetent cells [31,40]. 
The fully reduced HMGB1 isoform in  which all three cysteine residues are reduced, has 
chemoattractant properties. Notably, fully reduced HMGB1 forms a complex with 
CXCL12, which binds to the CXCR4 receptor. The chemoattractant activity of HMGB1 is 
dependent on this axis, and is suppressed by the oxidation of HMGB1 cysteines [39].   
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The biological activities mediated by reduced or disulfide HMGB1 are inhibited by the 
simultaneous sulphonation of all three cysteines C23, C45 and C106. This condition leads 
to the formation of sulfonyl-HMGB1 which has neither pro-inflammatory activity, nor 
chemoattractant, and probably represents a physiological mechanism activated to block 
the biological effects mediated by HMGB1 [40]. 
The non acetylated and fully reduced HMGB1 is the isoform present in the nucleus of 
cells under physiological conditions [42]. 
Disulfide extracellular HMGB1 is the predominant isoform released in conditions of 
oxidative stress [38]. After cell damage or epileptogenic insult, fully reduced HMGB1 
present in the nucleus, is acetylated and translocates into the cytoplasm, where interacts 
with free radicals, produced by oxidative stress, and is oxidized into disulfide HMGB1. 
 This mechanism creates a vicious circle that links cell damage or epileptogenic event, 
oxidative stress and the production of disulfide HMGB1 (Fig.3). 
 
Figure 3. Post-transcriptional modifications of HMGB1 (from Venereau et al, 2016) 
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Recent pharmacological studies demonstrated that disulfide HMGB1 isoform contributes 
to seizure recurrence [43]. The mechanism that mediates the effects of disulfide HMGB1 
is the same activated by IL-1β [23] and involves an increased activation of the N-Methyl-
D-Aspartate (NMDA) receptors that mediate the excitatory glutamatergic transmission 
during seizure [43] 
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2.2 AIMS OF STUDY 
Epilepsy therapy is based on antiseizure drugs which treat the symptom, seizures, rather 
than the disease and are ineffective in up to 30% of patients. There are no treatments for 
preventing the onset of epilepsy or improving disease prognosis.  
In this study, we investigated whether oxidative stress occurs in brain during 
epileptogenesis in a rat model of acquired epilepsy induced by electrical status epilepticus 
(SE) and if this pathological process is also present in hippocampus of humans who died 
following SE.  
Then, we studied whether HMGB1 traslocation, and its disulfide isoform that promotes 
seizures and cell loss, are generated by ROS during oxidative stress. 
Finally, we investigated if oxidative stress can be efficiently resolved by a transient 
treatment with N-acetyl-cysteine (NAC) and sulforaphane (SFN), two drugs known to 
raise the levels of the antioxidant glutathione (GSH) and already used in humans for other 
therapeutic indications. 
The main scope was testing their therapeutic effects on spontaneous seizures, cell loss and 
comorbidities.  
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2.3 MATERIALS AND METHODS 
2.3.1 Animals 
Adult male Sprague-Dawley rats (225–250 g; Charles-River, Calco, Italy) were housed at 
constant temperature (23 ± 1°C) and relative humidity (60 ± 5%) with free access to food 
and water and a fixed 12 h light/dark cycle. Procedures involving animals and their care 
were conducted in conformity with the institutional guidelines that are in compliance with 
national (D.L. n.26, G.U. March 4, 2014) and international laws and policies (EEC 
Council Directive 86/609, OJ L 358, 1, December 12, 1987; Guide for the Care and Use of 
Laboratory Animals, U.S. National Research Council, 1996) and were reviewed and 
approved by the intramural ethical committee. 
 
2.3.2 Electrical status epilepticus  
Rats were implanted under 1.5% isoﬂuorane anesthesia with 2 bipolar Teﬂon-insulated 
stainless-steel depth electrodes placed bilaterally into the temporal pole of the 
hippocampus (from bregma, mm: AP −4.7; L ± 5.0; −5.0 below dura) [44]. Two screw 
electrodes were positioned over the nasal sinus and the cerebellum, and used as ground 
and reference electrodes, respectively. Electrodes were connected to a multipin socket and 
secured to the skull by acrylic dental cement. After surgical procedures, rats were treated 
locally with Cicatrene powder (Neomicyn; Bacitracin; Glicyne; L-Cysteine; DL-
Threonine) and injected with Ampicillin (100 mg/kg, i.p.) for 4 days to prevent infections. 
Rats were allowed to recover from surgery in their home cage for 10 days. Before 
electrical stimulation, EEG baseline hippocampal activity was recorded in freely-moving 
rats for 24 h. Then, rats were unilaterally stimulated (50 Hz, 400 μA peak-to-peak, 1 ms 
biphasic square waves in 10 s trains delivered every 11 s) in the CA3 region of the ventral 
hippocampus for 90 min to induce SE according to a well established protocol [45,46]. 
43 
 
EEG was recorded in each rat every 10 min epoch for 1 min in the absence of electrical 
stimulation, i.e., the “stimulus-off” period. All rats used for subsequent analysis showed 
an EEG pattern of uninterrupted bilateral spikes in the hippocampi during the “stimulus-
off” period, starting between the 1st and the 4th epoch of stimulation onwards. These 
criteria selected rats developing SE that remitted spontaneously within 24 h from the 
initial stimulation then leading to subsequent epilepsy development [45,46]. SE was 
deﬁned by the appearance of continuous spike activity with a frequency >1.0 Hz 
intermixed with high amplitude and frequency discharges lasting for at least 5 s, with a 
frequency of ≥8 Hz. Spikes were deﬁned as sharp waves with amplitude at least 2.5-fold 
higher than baseline and duration lower than 100 ms, or as a spike-and-wave with duration 
lower than 200 ms [47]. The end of SE was deﬁned by the occurrence of inter-spike 
intervals longer than 1 s. No pharmacological intervention was done to stop SE since no 
mortality is observed in this model. SE was evaluated by EEG analysis measuring its total 
duration and the number of spikes during the ﬁrst 24 h using Clampﬁt 9.0 program (Axon 
Instruments, Union City, CA, U.S.A.). Power spectral density (PSD) distribution of 4 
frequency bands (delta: 1–4 Hz; theta: 4–8 Hz; alpha: 8–13 Hz; beta-gamma: 13–40 Hz) 
was calculated during 9 h segmented in temporal windows of 1 h each. Fast Fourier 
transforms (FFTs) were computed by 50% overlapping sliding windows (1024 data-point 
each) with Hanning windowing function. EEG data were normalized by dividing the EEG 
power density at each frequency with the EEG power density averaged across all 
frequencies [47]. 
 
2.3.3 Spontaneous seizures detection and quantification 
Rats exposed to electrical SE were continuously video-EEG recorded (24 h/day) from SE 
induction until the first 2 spontaneous seizures occurred, at least 48 h apart from SE 
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induction (epilepsy onset). All EEG seizures were associated with generalized motor 
seizures (forelimb clonus with or without rearing and/or falling) [46,48]. After epilepsy 
onset in each rat, video-EEG monitoring was discontinued and resumed at 2 months and 
4.5 months post-SE to determine spontaneous seizure frequency by continuous EEG 
monitoring for 2 weeks (24/7). Spontaneous seizures were discrete EEG ictal episodes 
lasting on average 60 s, characterized by high-frequency and high-voltage synchronous 
spike activity and/or multi-spike complexes [46]. EEG was recorded using the TWin EEG 
Recording System connected with a Comet AS-40 32/8 Ampliﬁer (sampling rate 400 Hz, 
high-pass ﬁlter 0.3 Hz, low-pass ﬁlter 70 Hz, sensitivity 2000 mV/cm; Grass-Telefactor, 
West Warwick, R.I., U.S.A.). Digitized EEG data were processed using the TWin record 
and review software. EEG was visually inspected for seizure detection and quantiﬁcation 
by two independent expert operators blinded to the treatments.  
 
2.3.4 Drug treatment 
To maximize the chances of therapeutic outcomes, we used two anti-oxidant drugs with 
complementary mechanisms of action that should reinforce each others. 
The first was the N-acetyl-cysteine (NAC), the precursor of GSH which represents the 
major non-enzymatic antioxidant pathway of the body. The second was the sulforaphane 
(SFN), a natural isothiocyanate derived from a glucosinate found in cruciferous 
vegetables, especially broccoli. SFN is a potent activator of the nuclear factor (erythroid-
derived 2)-like 2 (Nrf-2), a transcription factor that regulates the anti-oxidant response by 
promoting the activation of Antioxidant Responsive Elements (ARE). AREs are present in 
the promoters of different genes encoding for enzymes with detoxifying and anti-oxidant 
activity as glutathione s-transferase, glutathione peroxidase, NADPH: quinone 
oxidoreductase 1, heme-oxygenase 1, thioredoxin, and others [49]. 
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2.3.5 In vivo study design  
The first set of experiments was done to investigate the level of oxidative stress in the 
electrical model of SE-induced epileptogenesis. In each experiment, electrode-implanted 
rats not exposed to SE were used as controls (Sham). In one experiment, rats were 
exposed to SE and sacrificed 4 days (n=9) or 14 days (n=5) later for HPLC analysis of 
reduced (GSH), oxidized (GSSG) glutathione and glutathionylated proteins (GS-Pro) in 
the hippocampus vs sham rats (n=15) (Fig.4A). A different group of rats was sacrificed 4 
days post-SE (n=5 each group; Sham=4) for immunohistochemical analysis of inducible 
nitric oxide (iNOS), the cysteine transporter (Xct), the Nrf2 and HMGB1 (Fig.4B).  
In the subsequent set of experiments, SE-exposed rats were treated with NAC (Sigma-
Aldrich, St. Louis, MO, USA; 500 mg/kg dissolved in H2O, pH 7.4) and SFN (LKT 
Laboratories, St Paul, MN, USA; 5 mg/kg dissolved in 0.1% DMSO in buffered saline, pH 
7.4) either alone or in combination, or their vehicles.   
For determining the effect of each drug alone, or their combination, on oxidative stress 
(Fig. 5A), a cohort of rats (n=5 rats in each group) was treated with either NAC alone 
(twice/daily 6 h apart) for 7 days (Fig.15A, panel a) or SFN alone (5 mg/kg, i.p., once 
daily) for 14 days (Fig.15A, panel b), or NAC+SFN combination for 7 days (same 
schedule as each drug given alone) followed by SFN alone for additional 7 days (Fig. 
15A, panel c). In each treatment schedule, the first drug dose was injected 60 min after SE 
onset. In the combination protocol, SFN was injected 1 h after the first NAC 
administration. Rats were sacrificed at the end of each treatment for HPLC analysis of 
glutathione forms.  
For determining if oxidative stress was associated with the generation of disulfide 
HMGB1 (Fig.10; Fig.15B), a group of SE-exposed rats was treated with NAC+SFN (same 
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schedule as each drug given alone) or their vehicles for 4 days (n=11 each group), and 
compared to sham rats (n=15). Both glutathione forms and HMGB1 levels were measured 
in the hippocampus; HMGB1 was also measured in corresponding venous blood in each 
animal. 
To assess their therapeutic effect on spontaneous seizures, cell loss and cognitive deficits, 
NAC+SFN (same doses of each drug given alone) were co-administered for 7 days post-
SE followed by SFN administered alone for additional 7 days (Fig.15C; Figs.8 and 9). 
Rats were randomly assigned 1 h after SE onset to either drug (n=9) or vehicle groups 
(n=9), and EEG was recorded as previously described. At the end of EEG recording, rats 
underwent the T-Maze test, then they were sacrificed and blood and brain were collected 
for subsequent analysis. 
 
2.3.6 Blood collection 
In the cross-sectional study (Fig.10), blood was collected by the heart atrium at the time of 
sacrifice, i.e., 4 days after SE onset. In the longitudinal study (Fig.11), blood was drawn 
by the tail vein at the end of treatment (i.e., 14 days post-SE) in animals under light 
isofluorane anaesthesia placed on a warming pad to avoid hypothermia. Blood was drawn 
(~500 µl) using a butterfly (21G needle) and collected in VACUTAINER test tubes. 
Plasma was isolated according to standard procedures, aliquoted and stored at -80°C until 
assay. 
 
2.3.7 Rat brain histology and immunohistochemistry 
Rats were deeply anaesthetized using ketamine (75 mg/kg) and medetomidine (0.5 mg/kg) 
then perfused via the ascending aorta [50,51]. The brains were removed from skull and 
post-fixed for 90 min at 4°C, the transferred to 20% sucrose in phosphate buffered saline 
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(PBS) for 24 h at 4°C, frozen in n-pentane for 3 min at −50°C and stored at −80°C until 
assay. Serial horizontal sections (40 μm) were cut on a cryostat throughout the temporal 
extension of the hippocampus (7.6 to 4.6 mm from bregma) [44]. All evaluations were 
done by an experienced investigator blinded to the treatment. 
Nissl staining. Cell loss was measured as previously described [52,53]. Briefly, images of 
the whole hippocampus in each hemisphere were captured at 20X magnification using a 
BX61 microscope equipped with motorized platform (Olympus, Germany) and digitized. 
Quantification was done in 4 Nissl-stained horizontal sections of the stimulated temporal 
hippocampus in each rat brain. Neuronal cell loss was quantified by reckoning the number 
of Nissl-stained neurons in CA1 and CA3/CA4 pyramidal cell layers, the hilar 
interneurons and the entorhinal cortex. Nissl-positive cells were marked by one 
investigator blinded to the identity of the samples, and an automated cell count was 
generated using Fiji software. Data obtained in each section/area/rat were averaged, thus 
providing a single value for each area/rat, and this value was used for the statistical 
analysis. Although this cell counting method has some limitations as compared to design-
based stereological analysis [54], the occurrence of any bias in counting neurons should 
similarly affect control and experimental samples since these samples underwent the same 
methodological procedures in parallel. 
Immunohistochemistry. Inducible nitric oxide (iNOS), nuclear factor (erythroid-derived 
2)-like 2 (Nrf2) and system xc- cystine/glutamate antiporter (Xct) were assessed as 
established cellular markers of oxidative stress. For each rat brain, we used one set of 12 
consecutive slices, using 4 alternate slices for each marker. The effect of anti-oxidant drug 
combination on intracellular HMGB1 localization was evaluated (4 slices/rat). 
iNOS: slices were incubated at 4°C for 10 min in 1% H2O2 in PBS followed by 1 h 
incubation in 10% fetal bovine serum (FBS) in 0.4% Triton X-100 in PBS. Then, they 
48 
 
were incubated at 4°C with a primary anti-iNOS antibody (1:250, Abcam) in 10% FBS in 
0.2% Triton X -100 in PBS for 24 h. 
Nrf2: slices were incubated at 4°C for 30 min in 10% FBS in 0.4% Triton X-100 in PBS. 
Then, slices were incubated with a primary anti-Nrf2 antibody (1:1500, Santa Cruz, La 
Jolla, CA, USA) at 4°C in 10% FBS and 5% bovine serum albumin (BSA) in 0.1% Triton 
X-100 in PBS for 24 h. 
Xct: slices were incubated at 4°C for 30 min in 10% FBS in 0.2% Triton X-100 in PBS. 
Then, they were incubated at 4°C with a primary anti- Xct antibody (1:350; donated by 
Prof. La Bella) in 10% FBS and 5% BSA in 0.1% Triton X-100 in PBS for 24 hours. 
HMGB1: slices were incubated at 4°C for 1 h in 10% FBS in 0.1% Triton X-100 in PBS, 
followed by an overnight incubation with the primary antibody against HMGB1 (1:1000; 
Abcam, Cambridge, UK) at 4°C in 10% FBS in 0.1% Triton X-100 in PBS [34].  
All sections were reacted using DAB. For the co-localization experiments, we used 6 
additional slices per animal for each oxidative stress marker. After incubation with the 
primary antibody against iNOS or Nrf2 or Xct slices were incubated at 4°C with the 
secondary anti-rabbit antibody conjugated with Alexa488 (1:500; Molecular Probes) in 
0.4% Triton X-100 in PBS for 30 min. For HMGB1, slices were incubated with an anti-
rabbit biotinylated secondary antibody (1:200, Vector Labs, Burlingame, CA, USA), then 
in streptavidin–HRP and the signal was revealed with tyramide conjugated to Fluorescein 
using TSA amplification kit (NEN Life Science Products, Boston, MA, USA). The slices 
were then incubated at 4°C for 24 h in 3% FBS in 0.1% Triton X-100 in PBS with an 
antibody directed against the fibrillary acidic protein (GFAP, 1:3500, Chemicon), 
selective marker of astrocytes, or with an anti-OX-42 (1:100 antibody, Serotec), marker of 
microglial cells, or with an antibody against the neuronal nuclear protein (NeuN, 1:1000, 
Chemicon), or with mouse anti-rat endothelial protein (EBA, 1:10,000, Sternberger, 
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Lutherville, MD, USA) to identify microvessels. The fluorescence was detected using 
secondary antibodies conjugated with Alexa546 (1:250; MolecularProbes). Each slice was 
additionally incubated in Hoechst 33258 (1:500; Molecular Probes) in PBS to make the 
cell nuclei visible. The sections were then examined with an Olympus confocal 
microscope (BX61 microscope and confocal FV500) system using the 488 nm excitation 
waves (laser Ar) for fluorescein, of 546 nm (He-Ne Laser green) to Alexa546, and 350 nm 
(UV). 
Using 4 slices/rat/marker, calretinin and somatostatin immunostaining was performed to 
label hippocampal interneurons. For calretinin immunostaining, slices were incubated at 
room temperature (RT) for 30 min in 0.4% Triton X-100 in TBS, then for 90 min in 10% 
FBS followed by 24 h incubation with the primary antibody against calretinin (1:1000; 
Swant 7698) at RT in 10% FBS in 0.4% Triton X-100 in TBS. For somatostatin 
immunostaining, slices were incubated at RT for 2 h in 10% FBS, 0.1% BSA, 0.4% Triton 
X-100 in TBS, followed by 24 h incubation at RT with the primary antibody against 
somatostatin (1:2000; donated by Prof. Sperk) in 10% FBS, 0.1% BSA, 0.4% Triton X-
100 in TBS. The sections were reacted using DAB and the signal was amplified by nichel 
ammonium. Images of the whole hippocampus in each hemisphere were captured at 20X 
magnification using a BX61 microscope equipped with motorized platform (Olympus, 
Germany) and digitized. Calretinin and somatostatin immunopositive cells were identified 
in the hilus by one investigator blinded to the identity of the samples, and an automated 
cell count was generated using Fiji software. Data obtained in each of the 4 
sections/marker/rat were averaged, thus providing a single value for each marker in each 
rat, and this value was used for the statistical analysis. 
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2.3.8 Human subjects  
The cases included in this study were obtained from the archives of the departments of 
neuropathology of the Academic Medical Center (AMC, Amsterdam, The Netherlands) 
and the VU University medical center (VUmc, Amsterdam, The Netherlands). A total of 5 
hippocampal specimens (removed from patients undergoing surgery for drug-resistant 
epilepsy) and 11 hippocampal specimens obtained at autopsy from patients that died after 
SE were examined. Control material was obtained during autopsy of age-matched 
individuals without a history of seizures or other neurological diseases. Tissue was 
obtained and used in accordance with the Declaration of Helsinki and the AMC Research 
Code provided by the Medical Ethics Committee. All cases were reviewed independently 
by two neuropathologists and the classification of hippocampal sclerosis was based on 
analysis of microscopic examination as described by the International League Against 
Epilepsy [54]. The clinical features of the cases analysed are reported in Table 1. 
 
 Control 
(n=7) 
Hippocampal 
Sclerosis 
(n=5) 
Post-SE 
(n=11) 
Male/Female 4/3 2/3 4/7 
Mean age of surgery or 
death after SE (years) 
46 (25-76) 43.6 (35-62) 64 (31-87) 
Mean duration of 
epilepsy (years) 
Not applicable 17 (11-32) Not applicable 
Time of death after SE 
(days) 
Not applicable Not applicable 1-49 
 
Table 1. Summary of clinical features of cases according to pathology.  
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2.3.9 Immunohistochemistry in human brain 
Human brain tissue was fixed in 10% buffered formalin and embedded in paraffin. 
Paraffin-embedded tissue was sectioned at 5 µm, mounted on pre-coated glass slides (Star 
Frost, Waldemar Knittel, Braunschweig, Germany) and processed for 
immunohistochemical staining. Sections were deparaffinated in xylene, rinsed in ethanol 
(100%, 95%, 70%) and incubated for 20 minutes in 0.3% hydrogen peroxide diluted in 
methanol. Antigen retrieval was performed using a pressure cooker in Tris-EDTA buffer 
(10mM Tris + 1mM EDTA, pH 9) at 120°C for 10 minutes. Slides were washed with 
phosphate-buffered saline (PBS; 0.1 M, pH 7.4) and incubated overnight with primary 
antibody (anti-iNOS antibody, 1:250, Abcam; anti-Nrf2 antibody, 1:500, Santa Cruz ; 
anti-Xct antibody, 1:250)  in PBS at 4°C. For single labeling, after washing with PBS, 
sections were stained with a polymer based peroxidase immunohistochemistry detection 
kit (Brightvision plus kit, ImmunoLogic, Duiven, The Netherlands) according to the 
manufacturer’s instructions. Staining was performed using Bright DAB substrate solution 
(1:10 in 0.05 M Tris-HCl, pH 7.6; ImmunoLogic) with 0.015% H2O2. Sections were 
dehydrated in alcohol and xylene and coverslipped.  
For double labeling, sections with primary antibodies were incubated with Brightvision 
poly-alkaline phosphatase (AP)-anti-rabbit (Immunologic) and horseradish peroxidase 
labelled (HRP)- goat anti-mouse IgG (1:100, Southern Biotech, Birmingham, USA) for 1 
hour at room temperature. Primary antibodies for NeuN (neuronal nuclear protein, mouse 
clone MAB377; Chemicon, Temecula, CA, USA; 1:200) and GFAP (monoclonal mouse, 
Sigma, St. Louis, Mo, USA; 1:4000), were incubated overnight at 4°C. NeuN and GFAP 
staining was visualized with 3-amino-9-ethylcarbazole (AEC, Sigma-Aldrich, 
Zwijndrecht, Netherlands). 
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2.3.10 Analysis of HMGB1 isoforms by electrospray ionization liquid 
chromatography mass spectrometry  
Rats were deeply anesthetized using ketamine (75 mg/kg) and medetomidine (0.5 mg/kg), 
then rapidly perfused via the ascending aorta with 50 mM ice-cold PBS (pH 7.4) for 1 min 
to remove blood from brain vessels. Then, rats were decapitated, brain removed and the 
ventral hippocampi were dissected out at 4°C, immediately frozen in liquid nitrogen and 
stored at −80 °C. The analysis of the isoforms of HMGB1 was performed as previously 
described in detail [56]. Non-identifiable samples were analyzed by an investigator 
blinded to the identity of the samples. All chemicals and solvents were of the highest 
available grade (Sigma Aldrich, Dorset, UK). Samples were precleared with 50 μl protein 
G-Sepharose beads for 1 h at 4°C. Supernatant HMGB1 was immunoprecipitated with 5 
μg rabbit anti-HMGB1 (Abcam; ab18256) for 16 h at 4°C as previously described [57]. 
Free thiol groups within HMGB1 were alkylated for 90 min with 10 mM iodoacetamide at 
4°C. Cysteine residues in disulfide bonds were then reduced with 30 mM DTT at 4°C for 
1 h followed by alkylation of newly exposed thiol groups with 90 mM NEM at 4°C for 10 
min. Samples were subjected to trypsin (Promega, Southampton, UK) or GluC (New 
England Biolabs, Hitchin, UK) digestion according to manufacturer's instructions and 
desalted using ZipTip C18 pipette tips (Merck Millipore). Characterization of whole 
protein molecular weights, acetylated lysine residues, or redox modifications on cysteine 
residues within HMGB1 were determined as described previously by whole protein 
electrospray ionization or tandem mass spectrometry [56,57] using either an AB Sciex 
QTRAP 5500 or an AB Sciex TripleTOF 5600 (Sciex Inc., Warrington, UK). Peptide 
analysis was determined using an AB Sciex QTRAP 5500 equipped with a NanoSpray II 
source by in-line liquid chromatography using a U3000 HPLC System (Dionex, Thermo 
Fisher UK Ltd., Hemel Hempstead, UK), connected to a 180 μm × 20 mm nanoAcquity 
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UPLC C18 trap column and a 75 μm × 15 cm nanoAcquity UPLC BEH130 C18 column 
via reducing unions. A gradient from 0.05% TFA (v/v) to 50% ACN/0.08% TFA (v/v) in 
40 min was applied at a flow rate of 200 nl/min. The ionspray potential was set to 2200–
3500 V, the nebulizer gas to 19, and the interface heater to 150°C. 
The proteolitic digestions of HMGB1 required for LC/MS-MS analysis generates peptide 
fragments that either contain the acetylation sites or the redox sensitive sequence. 
Therefore, the results shown in Fig.10C,D and Fig.11B depict acetylated HMGB1 
separately from the reduced and disufide isoforms. Since reduced and disulfide HMGB1 
are mutually exclusive isoforms, their amounts account for total HMGB1 levels. Finally, 
HMGB1 isoforms in serum have been determined by a patented (USA US8748109 B2, 
Europe EP2449378, Japan 5721707) absolute quantification method [56,57] which has 
been extensively validated to bioanalytical guidelines set out by the SAFE-T IMI funded 
biomarker consortium (http://www.imi-safe-t.eu/). Since a method for absolute 
quantification of HMGB1 isoforms has not been extensively validated for brain tissue as 
yet, HMBG1 isoforms in brain are expressed as fold-change of respective basal values.  
Total HMGB1 was measured by a commercially available ELISA kit in accordance with 
manufacturer’s instructions (Shino-test Corp, Sagamihara, Japan). 
 
2.3.11 HPLC analysis of GSH, GSSG, GS-Pro 
The ventral hippocampus in each rat was longitudinally divided into two parts which were 
randomly used for the quantification of free GSH or GSSG, GS-Pro and glutathione 
precursors, respectively. The sample preparation and HPLC analysis were performed as 
previously described in detail [58]. The various molecules were identified in the 
chromatogram according to their different retention time, and subsequently quantified. 
Values were expressed as nmol of compound/mg tissue protein measured using the 
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bicinchoninic acid protein assay (BCA, Pierce, Rockford, Illinois, USA). The amount of 
total glutathione was calculated by summing free GSH, GSSG and GS-Pro. Samples were 
analyzed by an investigator blinded to their identity. 
The levels of GSH and GSSG in plasma were measured with an ESA (Chelmsford, MA) 
5600 CoulArray HPLC equipped with eight electrochemical cells following the method 
described previously [59].  
 
2.3.12 Behavioral test 
Hippocampal-dependent spatial memory was measured in a standard two arms T-maze 
apparatus (50x40x10 cm each arm) in rats undergoing the longitudinal study for seizure 
assessment at the end of EEG recording (i.e., 5 months post-SE). Animals were tested by 
an investigator blinded to their identity. Animals were placed into the starting arm of the 
T-maze and allowed to freely choose to enter one of the two arms in each of the seven 
trials. A successful alternation consisted of alternate arm entries while unsuccessful 
alternation occurred when the rat returned to the most recently explored arm. Total arm 
entries and sequence of entries were recorded for each rat and as percent of correct choice 
was reckoned, i.e., the number of correct alternations/the maximum number of alternations 
× 100. Rats with intact hippocampal-dependent spatial memory will remember the arm 
that was previously visited and will prefer to enter a new, unexplored arm (alternation rate 
≥ 60%). 
 
2.3.13 Cortical cell cultures 
Mixed cortical neurons and glial cells cultures were prepared from postnatal (P0-P1) 
Sprague-Dawley rat pups (UCL breeding colony) using an enzymatic procedure according 
to a modified protocol described by Haynes [60,61]. The pups were sacrificed by cervical 
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dislocation, and rat brains were quickly removed and neocortical tissue was isolated and 
submerged in ice-cold HBSS (Ca
2+
, Mg
2+-
free, Gibco-Invitrogen, Paisley, UK). The tissue 
was treated with 1% trypsin for 10 minutes at 37°C to dissociate cells. The final neuronal 
cell suspension was plated on 25 mm round coverslips coated with poly-L-lysine (1 
mg/ml, Sigma), and cultured in Neurobasal A medium (Gibco-Invitrogen) supplemented 
with B-27 (Gibco-Invitrogen) and 2 mM L-glutamine. Neocortical cultures were fed once 
a week and maintained in a humidified atmosphere of 5% CO2 and 95% air at 37 °C in a 
tissue culture incubator. The cultures were used for experiments at 13-17 DIV. Neurons 
were distinguished from glia by their typical appearance using phase-contrast imaging 
with smooth rounded somata, bright-phase and distinct processes. 
 
2.3.14 Imaging of intracellular Ca
2+
 ([Ca
2+
]c) and mitochondrial membrane potential 
(Δψm) 
Preincubations and experiments were performed at room temperature in an HEPES-
buffered salt solution (aCSF), composition in mM: 125 NaCl, 2.5 KCl, 2 MgCl2, 1.25 
KH2PO4, 2 CaCl2, 30 glucose and 25 HEPES, pH adjusted to 7.4 with NaOH.  
Experiments were carried out in either the HEPES buffered salt solution including (aCSF) 
or excluding MgCl2 (low Mg
2+
) [60]. Before recording, neocortical neuronal cultures were 
incubated for 30 minutes with 5 μM Fura-2-AM (Invitrogen, Paisley, UK), and 0.005% 
pluronic acid in aCSF. 
For simultaneous measurement of [Ca
2+
]c and Δψm, Rhodamine123 (Rh123) (Sigma, UK) 
(2 μM) was added into the culture dishes during the last 15 minutes of the Fura-2-AM 
loading period. Cells were then washed 3 times prior to recordings. Fluorescence images 
were made on an epifluorescence inverted microscope equipped with a 20X fluorite 
objective. Measurements of [Ca
2+
]c and mitochondrial membrane potential were 
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performed in single cells using excitation light provided by a xenon arc lamp, the beam 
passing through a monochromator at 340, 380, and 490 nm with bandwidth of 10 nm 
(Cairn Research, Faversham, UK). Emitted fluorescent light was reflected through a 515 
nm long-pass filter to a cooled CCD camera (Retiga; QImaging) and digitised to 12-bit 
resolution. Imaging data were analysed using software from Andor (Belfast, UK). Traces 
are presented as the ratio of excitation at 340 and 380 nm, both with emission at >515 nm. 
We acquired fluorescent data with a frame interval of 10 seconds. [Ca
2+
]c was expressed 
by the Fura ratio and was not calibrated because of inaccuracies arising from different 
calibration methods. An increase of Rhodamine123 signal indicates depolarisation of 
mitochondria. Rhodamine123 signals were normalised to the baseline level (set 0) and 
maximum signal produced by mitochondrial oxidative phosphorylation uncoupling with 
carbonylcyanide-p-trifluoromethoxyphenyl hydrazone (FCCP, 1 μM; set to 100). Each 
experiment was repeated 2-3 times using 3-4 different cultures. 
 
2.3.15 Statistical analysis 
Sample size was a priori determined based on previous experience with the epilepsy 
model as well as following the principles of the 3 Rs (Replacement, Reduction and 
Refinement; https://www.nc3rs.org.uk/the-3rs). Endpoints (outcome measures) and 
statistical tests were prospectively selected. A simple random allocation was applied to 
assign a subject to a particular experimental group. All efforts were made to minimize the 
number of animals used and their suffering. Data acquisition and analysis was done 
blindly. 
Statistical analysis was performed by GraphPad Prism 7 (GraphPad Software, USA) for 
Windows using absolute values. Data are presented as mean ± s.e.m. (n = number of 
individual samples). Mann–Whitney test for two independent groups and Kruskal-Wallis 
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followed by Dunn’s post-hoc test for more than two independent groups were used for 
statistical analysis of data. In the longitudinal study, changes in time to seizure onset were 
analyzed by Log-rank (Mantel Cox) test. The temporal distribution of spikes during SE 
was analysed by two-way ANOVA followed by Bonferroni’s multiple comparisons test. 
Differences were considered significant with a p<0.05. 
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2.4 RESULTS 
2.4.1 Assessment of oxidative stress during epileptogenesis 
We studied whether oxidative stress was generated during epileptogenesis in SE-exposed 
rats by measuring the hippocampal levels of oxidized (GSSG) and reduced glutathione 
(GSH) and their ratio (GSSG/GSH) which is an established indicator of reactive oxygen 
species (ROS) production [12,63]. We choose two time points post-SE reflecting early 
epileptogenesis (before the onset of epilepsy, i.e. 4 days) and shortly after disease onset 
(when the treatment was stopped, i.e., 14 days). As previously reported in other rodent 
models of epileptogenesis, the levels of both GSH and GSSG significantly changed 
(p<0.01) between 4 days and 14 days post-SE (n=5-9) resulting in a progressive 3- to 14-
fold increase in GSSG/GSH ratio above control values (in sham rats not exposed to SE, 
n=15) (Fig. 4A). A concomitant increase in glutathionylated proteins (Gs-Pro) was 
measured in the same hippocampal tissue (Fig. 4A). To determine which cell types were 
undergoing oxidative stress, immunohistochemical analysis was done in a different cohort 
of rats, 4 days post-SE. Fig. 4B depicts the cellular expression of molecular markers of 
oxidative stress, namely iNOS (a,b), the cystine transporter (Xct; c,d) and the 
transcriptional factor Nrf2 (e,f). These molecules were induced in activated GFAP-
positive astrocytes (b1,d1,f1) as well as in NeuN-positive neurons (b2,d2,f2) but not in OX-
42-positive microglia (not shown). In particular, we found increased Nrf2 staining in 
neuronal nuclei (f2 vs e1)  likely reflecting transcriptional activation of anti-oxidant 
enzyme genes in response to ROS production [64-66].  
 
2.4.2 Anti-oxidant drug combination vs single treatment 
In order to design the optimal treatment protocol for the therapeutic study (Fig. 15C), we 
tested whether a combination of NAC and SFN, two anti-oxidant drugs with 
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complementary mechanism of action, was more effective in reducing oxidative stress than 
each drug given alone. We designed a treatment schedule of 14 days to encompass the 
time window between the epileptogenic injury (i.e., SE) and the early phase after disease 
onset. Then, treatment was stopped for determining whether antiepileptogenic or disease-
modification therapeutic effects occur after drug withdrawal. Based on the available PK 
and PD information  [67-72] we treated different cohorts of rats with either NAC (500 
mg/kg, i.p., twice/day for 7 days) or SFN alone (5 mg/kg, i.p., once daily for 14 days), or 
their combination (NAC+SFN injected for 7 days followed by SFN injected alone for 
additional 7 days). Treatment began 1 h after the onset of SE (Fig. 15A). NAC was 
administered to rats for 1 week to attain a rapid scavenging action of ROS during SE [73]. 
SFN was administered for one additional week after NAC withdrawal to provide a 
sustained anti-oxidant effect [73]. Fig. 5A shows that GSH and GSSG were modified by 
SE resulting in a significant increase in GSSG/GSH ratio (p<0.01 vs sham, n=5 each 
group). Each drug alone increased GSH and reduced GSSG compared to SE-exposed rats 
receiving vehicles (p<0.01, n=5 each group). However, the combination of NAC and SFN 
showed a greater effect vs single drugs (p<0.01) in normalizing both GSH and GSSG 
levels and their ratio. Similarly, Gs-Pro level returned to sham value after the drug 
combination whereas it was still significantly elevated in rats treated with each drug alone.   
We further tested whether the drug combination was more effective than the individual 
drugs in preventing mitochondrial dysfunction using primary neuronal cortical cultures 
where epileptiform activity was induced by removing extracellular Mg
2+
 (Fig.6). We 
measured the changes in the mitochondrial inner membrane potential evoked by 
epileptiform activity and the effects of drugs. Fig.5B shows a progressive increase in 
mitochondrial membrane depolarization which was positively correlated with the time of 
exposure to low Mg
2+
-induced epileptiform activity (from 10 to 30 min; Fig. 6B). This 
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effect was significantly reduced by preincubation with SFN or NAC alone; notably, NAC 
induced membrane hyperpolarization (p<0.01 vs respective aCSF in Fig. 5B; Fig. 6C,D). 
The combination of NAC+SFN was more effective in preventing inner membrane 
depolarization and increasing membrane hyperpolarization than each drug alone (at 25 and 
30 min; p<0.01 vs each drug alone; Fig. 5B; Fig. 6E).  
 
2.4.3 Therapeutic effects of antioxidant drug combination in SE-exposed rats 
The combined treatment protocol was applied starting 1 h after SE onset (Fig. 15C). The 
drug combination did not attenuate the overall severity of the initiating injury, namely the 
duration of SE, or the frequency of spikes and their total number, as quantified by 
continuous EEG analysis for 24 h from SE onset. No difference was detected between the 
treatment and vehicle groups in the relative power distribution for each band during SE 
(Fig. 7B,C).  
 
2.4.4 Spontaneous seizures onset and their progression 
Rats exposed to SE and injected with vehicle developed spontaneous recurrent seizures 
(SRS) 8.6 ± 0.7 days (n=9) after SE onset (Fig.8A,B). Rats treated for 2 weeks during 
epileptogenesis with NAC+SFN showed a significant delay in the time to seizure onset 
(11.7±1.1 days, n=9, p<0.01) compared to vehicle-injected controls (Fig.8B). This 
epilepsy model is characterized by an average 5-fold increase in SRS frequency between 2 
months (5.1 ± 1.8 SRS/2 weeks) and 5 months (24.2 ± 7.7 SRS/2 weeks) post-SE. 
Although the number of seizures was not significantly modified by the drugs during 
treatment (3.6 ± 0.9, n=9) as compared to their vehicle controls (2.4 ± 0.5, n=9), SRS 
progression was prevented in drug-exposed rats after treatment withdrawal (Fig.8C, 
p<0.01 vs vehicle). Overall, drug-treated rats showed ~70% SRS reduction at 5 months 
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post-SE compared to vehicle-injected rats (p<0.05; Fig.8C). Total SRS duration during 2-
week EEG recording at 5 months was significantly reduced by drugs compared to vehicle 
controls (p<0.05; Fig.8D). 
 
2.4.5 Cognitive deficits 
Rats were tested in the T-maze at the end of EEG recordings (i.e. 5 months post-SE). SE-
exposed animals treated with vehicles showed an impairment of spatial memory in the T-
maze, as shown by failure of correct alternation in the entry arm of the maze (40.5 ± 2.8% 
correct alternation, n=9, p<0.01) compared to sham rats (66.8 ± 3.9% correct alternation, 
n=9) (Fig.8E). The drug combination rescued this behavioral deficit as shown by the 
correct alternation rate (68.4 ± 5.0%, n=9) of treated rats which was similar to sham rats 
(Fig.8E). No differences in locomotion were detected among the experimental groups in 
the open field task (not shown). All rats were confirmed to be epileptic before the T-maze 
test (Fig.8C) but they did not show behavioral seizures during the test. 
 
2.4.6 Neurodegeneration 
At the end of behavioral test, rats were killed for quantitative analysis of cell loss in Nissl-
stained forebrain sections of the ventral pole of the stimulated hippocampus (Fig.9; rats 
are the same reported in Fig.8). Vehicle-injected rats showed significant neuronal cell loss 
in CA1 and CA3 pyramidal cell layers and hilar interneurons (about 40% decrease vs 
sham rats; p<0.01; Fig.9A,B). The anti-oxidant treatment reduced cell loss by half in CA1 
(p<0.05; panel A) and virtually prevented the neurodegeneration of hilar interneurons 
(p<0.01; panel B). In particular, hilar calretinin- (but not somatostatin, not shown) positive 
cells were significantly protected by the drug combination (panel C). No significant 
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neuroprotection was observed in CA3, the region of electrical stimulation, or in adjacent 
entorhinal cortex (not shown). 
 
2.4.7 Effects of the anti-oxidant drug combination on the redox state of HMGB1 
We tested the novel hypothesis that reduction of oxidative stress during epileptogenesis 
prevents the generation of the pathologic disulfide HMGB1 isoform in the brain. We 
found that NAC+SFN decreased oxidative stress already 4 days post-SE (Fig. 10A), and 
this effect was similar when treatment was started 1 h (Fig.10A) after SE onset. At the 
same time point, we found immunohistochemical evidence of nucleus-to-cytoplasm 
translocation of HMGB1 in astrocytes, microglia and brain endothelium of SE-exposed 
rats (Fig. 10B, panel b vs a) which is indicative of its extracellular release. Accordingly, 
LC-MS/MS measurements of HMGB1 isoforms in the hippocampus  showed a 10-fold 
increase of the acetylated (releasable) HMGB1 isoform 4 days post-SE compared to sham 
rats (Fig. 10C; p<0.01 vs sham; n=9-11). We also found that the pathologic disulfide 
HMGB1 isoform, which is absent in control brain tissue, is generated during 
epileptogenesis (Fig. 10C; p<0.01 vs sham; n=9-11). The increase in both acetylated and 
disulfide HMGB1 (Fig. 10C), as well as the cytoplasmatic translocation of HMGB1 (Fig. 
10B, panel c vs b), were abolished by NAC+SFN. We also detected a minor but 
significant increase (p<0.01) in reduced HMGB1 during epileptogenesis which is the 
constitutive isoform bound to nuclear chromatin (Fig. 10C). NAC+SFN blocked also the 
reduced and total HMGB1 increase (Fig. 10C). Notably, the changes in brain HMGB1, 
and the effects of treatment, were similarly detected in the blood of the same animals (Fig. 
10D). 
Based on these findings, we measured the GSSG/GSH ratio as well as total HMGB1 and 
its isoforms in the blood of SE-exposed rats undergoing the therapeutic trial (same rats as 
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in Fig.8). Blood was drawn by tail vein at the end of treatment (i.e., 14 days post-SE). 
GSSG/GSH ratio (Fig. 11A; p<0.05), total HMGB1 and its isoforms (Fig. 11B; Fig. 2; 
p<0.01) were increased in blood of SE-exposed rats compared to sham rats. All these 
effects were prevented by drug treatment (Fig.  11A,B).  
 
2.4.8 Oxidative stress in brain specimens from patients with status epilepticus and in 
temporal lobe epilepsy 
We used immunohistochemistry to analyze the presence of oxidative stress markers in 
autoptic hippocampal specimens from patients experiencing SE as well as in surgically 
resected human hippocampal tissue from temporal lobe epilepsy (TLE). Fig. 12 shows 
increased expression of iNOS, Xct and Nrf2 in NeuN-positive neuronal cells and GFAP-
positive astrocytes in a patient who died 49 days after SE. Nrf2 signal was increased 
prominently in cell nuclei, an indication of its nuclear translocation. A similar pattern of 
cellular expression of these markers was observed in SE patient specimens evaluated 
between 1 and 49 days post-SE and in chronic epilepsy hippocampal tissue from TLE 
patients (Fig. 13). Notably, HMGB1 cytoplasmatic staining was increased in both neurons 
and astrocytes in adjacent slices (Fig. 14), in accordance with previous finding in human 
TLE [34]. 
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2.5 DISCUSSION 
After brain injury and during seizures, mitochondrial dysfunction and increased NADPH 
oxidase and xanthine oxidase activities lead to excessive generation of ROS, thereby 
contributing to neuropathology [11,62]. Indeed, animal models of acquired epilepsy 
provide evidence of profound changes in mitochondrial function and ROS production as a 
result of various epileptogenic injuries. These alterations occur rapidly after the inciting 
event, persist during epileptogenesis and are still observed in the chronic epilepsy phase 
[12,19,75]. It is likely that the mechanisms leading to oxidative tissue damage vary in the 
different phases of the epileptic process [11]. It remains to be determined if, and by which 
mechanisms, ROS generation contribute to the onset and recurrence of spontaneous 
seizures. Importantly, whether targeting oxidative stress has any effect on epileptogenesis 
is still unresolved.  
Our novel findings show that a transient post-injury intervention with a specific 
combination of antioxidant drugs, namely NAC and SFN, mediates clinically relevant 
therapeutic effects in a rat model of acquired epilepsy. This combined treatment was more 
effective in rescuing mitochondrial dysfunction and reducing oxidative stress during 
epileptogenesis than the single drugs alone. Both NAC and SFN were previously shown to 
provide neuroprotection in various brain injury models [65,76-78] and displayed 
anticonvulsive properties in animal models of acute seizures [65,78,79].  Notably, NAC 
showed anticonvulsive effects in human progressive myoclonus epilepsy [80].   
Oxidative stress has been implicated in cell loss and cognitive dysfunctions developing 
during epileptogenesis in different animal models [81-84]. Accordingly, our drug 
combination afforded neuroprotection and rescued cognitive deficits in a 
reference/working memory test by preventing the persistence of oxidative stress during 
epileptogenesis. Neuroprotection is compatible with the role of ROS in glutamate 
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excitotoxicity as well as in apoptotic cell death [85-87]. Additionally, we show that 
calretinin-positive cells in dentate hilus are particularly sensitive to neuroprotection 
mediated by our drug combination. These hilar interneurons form a subpopulation of 
GABAergic cells with frequent axo-dendritic and dendro-dendritric contacts with other 
inhibitory interneurons. This unique connectivity may enable them to play a crucial role in 
the generation of synchronous, rhythmic hippocampal activity by controlling other 
interneurons terminating on dendritic and somatic compartments of principal cells [88], 
therefore they are suggested to play a key role in the hippocampal inhibitory network. 
Notably, the density of calretinin-immunopositive cells is decreased significantly in the 
sclerotic hippocampus from human TLE, a phenomenon that may contribute to seizure 
generation and recurrence [89]. Whether neuroprotection plays a role in the rescue of 
cognitive deficit in the T-maze remains speculative. Similar positive effects on cognitive 
dysfunctions were recently reported using SFN in a model of okadaic acid-induced 
memory impairment [90] or using a metalloporphyrin catalytic antioxidant in a rat model 
of pilocarpine-induced epileptogenesis [84]. However, at variance with the lack of effect 
of antioxidant intervention on SRS reported in a previous study [84], our combined 
treatment significantly delayed epilepsy onset and induced a long-term reduction in 
spontaneous seizure frequency and duration compared to vehicle-injected rats. It is 
possible that our drug combination is particularly effective in antagonizing oxidative stress 
damage contributing to SRS. One major difference may be due to the mechanism of 
antioxidant action of direct antioxidants used in previous studies vs Nrf2 inducer used in 
this study. The latter induces multiple genes many of which encode endogenous 
antioxidants resulting in longer-lasting effects [74]. Another factor possibly explaining the 
difference in results is the longer video-EEG monitoring of our study until the late phases 
of disease development which allowed to appreciate the effect of antioxidant treatment on 
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seizure progression. Our study is therefore the first report showing that antioxidant 
intervention applied for a limited time post-injury arrests the progression of epilepsy 
resulting in a strong reduction of SRS in the chronic epilepsy phase. Since these 
therapeutic effects outlasted by several weeks the end of treatment, they indicate that our 
antioxidant drugs mediate disease-modifying effects. Similar effects on spontaneous 
seizures progression were recently reported using an inducible nitric oxide inhibitor 
reducing reactive nitrogen species [91]. 
Disturbances in the normal redox state of the cells may contribute to epileptogenesis in 
various manners. There is evidence of at least two potential links between mitochondrial 
oxidative stress and increased neuronal excitability, namely bioenergetic failure due to 
increased demand for neuronal mitochondria to produce cellular energy during 
hyperexcitability phenomena, and metabolic fuel utilization [11]. Moreover, neuronal 
excitability is controlled by glutamate and GABA, the biosynthesis of which depends on 
mitochondria [92]. ROS have the potential to influence epileptogenesis also via oxidative 
damage to macromolecules including proteins, lipids, and DNA. We tested the novel 
hypothesis that a pathological switch in the redox state of brain tissue during 
epileptogenesis leads to the generation of disulfide HMGB1, a proinflammatory molecules 
with neuromodulatory and ictogenic properties  [34,35,43,93]. Studies in literature showed 
that disulfide HMGB1 contributes to seizure generation and excitotoxic cell loss by 
activation of TLR4 and RAGE [34,35] and mice lacking either one of these receptors 
develop a milder form of epilepsy following SE [35]. Moreover, HMGB1 by activating 
TLR4 and RAGE mediated cognitive dysfunctions in mice [94]. Overall, this set of 
evidence supports the novel concept that disulfide HMGB1 may be a key mediator of the 
pathological effects of oxidative stress during epileptogenesis. In accordance, we found 
that the antioxidant effects of our drug combination were associated with prevention of 
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disulfide HMGB1 generation and extracellular release in brain tissue. Notably, the brain 
changes measured during epileptogenesis in total HMGB1 and its isoforms, as well as in 
oxidative stress indicators, were mirrored by similar changes in blood, and the blood 
levels of these molecules were modified by the antioxidant intervention similarly to the 
brain. Thus, these molecules may be potential biomarkers for determining the efficacy of 
the anti-oxidant drugs on their targets and possibly predicting their therapeutic effects.  
The translation of our findings to the clinical setting is supported by our fresh evidence 
that oxidative stress occurs in brain of patients experiencing SE, as well as in patients with 
drug-resistant TLE, and this phenomenon is associated with cytoplasmatic translocation of 
HMGB1 in neurons and glia.  Moreover, both NAC and SFN have been used in human 
clinical trials at doses comparable with the effective doses in our study. In particular, after 
extrapolating the human equivalent dose [95], we found that NAC and SFN doses in rats 
correspond to 5 g twice/daily and to 48 mg/daily for a 60 kg person, respectively. 
Interestingly, an intravenous infusion of 150 mg/kg NAC (corresponding to 9 g in a 60 kg 
person) in healthy individuals or Parkinson's and Gaucher's disease patients was well 
tolerated and resulted in increased brain GSH as assessed by magnetic resonance 
spectroscopy [96]. Moreover, NAC doses up to 3.6 g/day for several weeks have been 
used in neurological and psychiatric disorders [97]. In epilepsy clinical studies, NAC was 
used up to 6 g/daily for several months in progressive myoclonus epilepsy, in particular in 
Unverricht–Lundborg Disease with evidence of seizure improvement [97]. NAC seemed 
to be fairly well tolerated with no significant between group differences in most of the 
controlled trials. As far as SFN is concerned, clinical studies in cancer used daily doses of 
60 mg [97], and up to 27 mg were administered daily in autism spectrum disorders [99] 
with signs of improvement and a safety profile.  
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In summary, our findings have high translational value since we report novel evidence 
that: 1. oxidative stress markers occur in the hippocampus of humans who died following 
SE or with chronic pharmacoresistant epilepsy; 2. the drug doses we used in animals are 
compatible with human doses in the therapeutic range given for protracted treatment 
periods.   
Noteworthy, symptomatic (structural/lesional) epilepsies are often associated with a worse 
prognosis, therefore providing an ideal patients population for testing antioxidant drugs 
with potential disease-modifying properties [100,101]. 
.  
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2.6 FIGURES AND LEGENDS 
 
Figures 1-3 (included in the main text) 
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Figure 4. Generation of oxidative stress in hippocampal tissue of rats exposed to 
electrical SE 
Panel A: HPLC analysis of reduced (GSH) and oxidized (GSSG) glutathione levels, and their 
ratio, and the level of glutathionylated proteins (GS-Pro) in the rat hippocampus at day 4 (n=9) and 
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14 (n=5) after SE onset compared to corresponding baseline levels in sham rats (electrode-
implanted but not stimulated, n=15). Data (mean ± SEM) represent the percent changes compared 
to sham. *p<0.05; **p<0.01 vs sham by Kruskal-Wallis followed by Dunn’s post-hoc test; 
#p<0.05; ##p<0.01 vs day 4 by Mann-Whitney test. Statistical analysis of data was done using 
absolute values.  
Panel B: Representative immunohistochemical micrographs of the CA1 region depicting the 
expression of inducible nitric oxide (iNOS), the cysteine transporter (Xct) and the transcriptional 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in sham (a,c,e) and 4 days post-SE (b,d,f) (n=4 
each experimental group). Panels b,d,f show the increase in the respective marker expression in 
GFAP-positive astrocytes (b1,d1,f1) and in neurons (b2,d2,f2). Nrf2 expression is increased in 
neuronal nuclei (f2 vs e1) indicating increased transcriptional activation of detoxifying enzymes. 
Scale bar, a-f 25 µm; insert in b,d,f 15 µm; immunofluorescence insert, 10 µm.  
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Figure 5. Effect of drug combination vs single drug alone on oxidative stress markers 
Panel (A) reports GSH and GSSG levels, and their ratio, and GS-Pro levels in the hippocampus of 
rats exposed to SE vs sham rats as assessed by HPLC analysis. SE-exposed rats (n= 5 each group) 
received either vehicle combination, or NAC (500 mg/kg, i.p., twice daily for 7 days) or SFN (5 
mg/kg, i.p., daily for 14 days) or their combination (NAC+SFN for 7 days followed by SFN alone 
for additional 7 days; Fig. 15A). Controls were sham rats injected with vehicle (n= 5). The drug 
combination reduced oxidative stress to a greater extent than each drug given alone. *p<0.01 vs 
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Sham; °p<0.01 vs SE+ NAC+ SFN; #p<0.01 vs SE+vehicle by Kruskal-Wallis followed by 
Dunn’s post-hoc test. 
Panel B: Bargrams depict low Mg
2+
-induced mitochondrial membrane potential changes of 
neocortical cell cultures (Fig. 6B-E). Preincubation of neurons with SFN (5 M, 24h) decreased 
the rate of depolarization at all time points. Addition of NAC (10 mM, acutely) evoked 
hyperpolarization in the mitochondrial membrane potential. Pre-treatment with SFN (5 M, 24h) 
with addition of NAC (10 mM, acutely) showed similar effect as NAC alone, with significantly 
higher hyperpolarization after 25 and 30 min. *p<0.01 vs aCSF; #p<0.01 vs low Mg
2+
; °p<0.01 vs 
NAC+SFN by one-way ANOVA followed by Kruskall-Wallis test. 
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Figure 6. Low-Mg2+-induced Ca2+ signals and mitochondrial depolarization in 
neurons 
 Replacement of aCSF with low-Mg2+ aCSF induced synchronous oscillatory Ca2+ signals (A) 
and mitochondrial depolarization (i.e., increase of Rhodamine123 fluorescence) (B). Treatment 
with SFN (5 μM, 24h) induces a significant decrease of the effect of low-Mg2+ aCSF on 
mitochondrial membrane potential in neurons (C). NAC (10 mM, acutely) produced 
hyperpolarization in the mitochondria (D) and this effect was also observed when neurons were 
pre-treated with SFN (5 mM, 24h; E). Data are mean ±SEM of 80-100 neurons of one coverslip. 
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Figure 7 . Experimental model of SE-induced epilepsy and related injection protocol 
Panel (A). Brain atlas plate depicting electrode stimulation site in the CA3 area of temporal 
hippocampus. The schematic skull reproduction shows surface reference and ground electrode 
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placement and the position of the depth hippocampal electrodes. Representative EEG tracing 
depicting spike activity occurring during SE as recorded in the left (LHP) and right (RHP) 
hippocampi. Panel (B). Temporal spike distribution during SE in rats subsequently randomized 1 h 
after SE onset in vehicle or treatment groups. Each point represents the cumulative number of 
spikes during progressive 1 h intervals. Curves did not differ by two-way ANOVA followed by 
Bonferroni’s multiple comparisons test. NAC (500 mg/kg, i.p.) was given 1 h after SE onset 
followed 1 h later by SFN (5 mg/kg, i.p.), then a second NAC injection was done 6 h after the first 
NAC injection. Rats were treated in the following days as depicted in Fig. 15C. Panel (C) depicts 
the total duration of SE in the two experimental groups. The end of SE was deﬁned by the 
occurrence of inter-spike intervals longer than 1 sec. Panel (D) depicts frequency bands (delta, 
theta, alpha, beta-gamma) expressed as percent relative power for each hour of SE in vehicle- and 
drug-treated rats. Data were analyzed by two-way repeated measures ANOVA. Data are 
mean±SEM (n=9 each group). 
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Figure 8. Therapeutic effects of antioxidant drug combination in SE-exposed rats  
Panel A depicts a typical EEG recorded spontaneous seizure in a chronically epileptic rat injected 
with vehicle. LHP and RHP are left and right hippocampus, respectively. Panel B shows the onset 
of epilepsy (first spontaneous seizure) which was significantly delayed by the treatment (p<0.01 
by long-rank test, n=9 each group). Panel C reports the number of seizures during 2-week EEG 
recording at 2 months and 5 months post-SE in vehicle- and drug-treated rats (Fig. 15C). The data 
show that seizure progression was prevented by the treatment resulting in 70% SRS reduction at 5 
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months vs vehicle injected SE-exposed rats (**p<0.01 vs 2 months; #p<0.05 vs SE+Vehicle by 
Mann-Whitney test). Panel (D) depicts the average total duration of spontaneous seizures (SRS) 
recorded by EEG for 2 weeks at 5 months post-SE; this parameter was reduced by treatment vs 
vehicle (*p<0.05 vs SE+Vehicle by Mann-Whitney test). Panel (E) reports the rat performance in 
the T-maze showing the average percent of correct alternation in the each arm in the various 
experimental groups. The drug combination rescued the behavioral deficit in the epileptic rats. 
**p<0.01 vs Sham (n=8); ##p<0.01 vs SE+vehicle by Kruskal-Wallis followed by Dunn’s post-
hoc test.  
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Figure 9. Histological analysis and quantification of cell loss in the hippocampus of 
SE--exposed rats treated with the anti-oxidant drugs vs vehicles 
Panels depict representative microphotographs of Nissl-stained neurons in CA1 pyramidal layer 
(A) and in the hilus (B) and calretinin-stained hilar interneurons (C) in control (Sham+Vehicle) 
and epileptic rats treated with vehicle (SE+Vehicle) or the anti-oxidant drugs (SE+NAC+SFN; 
same rats of Fig. 8). Bargrams (mean ± SEM) report the correspondent quantification of cell loss.  
Data show the neuroprotective effect of the treatment. Scale bar: A,B 100 µm; C 50 µm. GC: 
granule cell layer; h: hilus; CA1: CA1 pyramidal cell layer of the hippocampus**p<0.01 vs 
Sham+Vehicle; #p<0.05, ##p<0.01 vs SE+Vehicle by Kruskall-Wallis followed by Dunn’s post-
hoc test.  
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Figure 10. Effect of anti-oxidant treatment on HMGB1 isoforms in brain and blood 
Bargram in (A) shows the increase in GSSG/GSH ratio during epileptogenesis (i.e., 4 days post-
SE) and its reduction to baseline (Sham+vehicle, n=15) by 4 day treatment with NAC (5 mg/kg, 
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i.p. twice daily) + SFN (5 mg/kg, i.p., once daily) (n=11) (Fig. 15B; treatment was started 1 h post-
SE). **p<0.01 vs Sham+vehicle; ##p<0.01 vs SE+vehicle by Kruskal-Wallis followed by Dunn’s 
post-hoc test. 
Panel (B) depicts representative photomicrographs of stratum lacunosum-moleculare of 
hippocampi from control rats (Sham) or SE-exposed rats treated with vehicle or NAC+SFN (n=5 
each group; treatment protocol is the same as in panel A). (a) HMGB1 immunoreactivity is 
localized in cell nuclei in sham rats; (b) HMGB1 immunoreactivity is increased in cytoplasm of 
glial cells (arrows, b) following SE; (c) reduced cytoplasmatic staining in SE-exposed rats treated 
with NAC+SFN denoting inhibition of HMGB1 nuclear-to-cytoplasm translocation. Second row 
shows HMGB1 signal (green) in OX-42-positive microglia (red), GFAP-positive astrocytes (red) 
and EBA-positive endothelial cells (red); co-localization signal is depicted in yellow (merge). 
White arrows represent cytoplasmic staining. Hoechst-positive nuclei are shown in blue. Scale bar: 
first row 25 µm; second row 12 µm. 
Bargrams in (C,D) show levels (mean ± SEM, n=9-11) of HMGB1 (acetylated, disulfide and 
reduced) isoforms in brain tissue (hippocampus, C) and corresponding blood (D) of rats during 
epileptogenesis (i.e., 4 days post-SE), and the effect of treatment. NAC+SFN abolished the 
increase in acetylated (releasable) and disulfide (pathogenic) HMGB1 isoforms in brain (B) and in 
blood (C). Total and reduced HMGB1 were also decreased by the treatment. **p<0.01 vs 
Sham+vehicle; ##p<0.01 vs SE+vehicle by Kruskal-Wallis followed by Dunn’s post-hoc test. 
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Figure 11. Oxidative stress markers and HMGB1 isoforms in blood 
Bargrams (mean ± SEM, n=9-10) reports GSSG/GSH ratio (A) and total HMGB1 and its isoforms 
(B) in blood of SE-exposed rats injected with either vehicle or antioxidant drug combination 
(NAC+SFN) (same rats as in Fig. 8) compared to baseline values in sham rats (Sham+Vehicle). 
Blood was drawn by the tail vein at the end of treatment (i.e., 14 days post-SE) then rats were 
followed up for monitoring SRS at 2 and 5 months post-SE (Fig. 15C). Notably, the blood levels 
of the molecules reflect their brain changes (Figs. 1, 2 and 5) and, as in brain, they were 
normalized by the treatment. **p<0.01 vs Sham; #p<0.05 vs SE+Vehicle by Kruskal-Wallis 
followed by Dunn’s post-hoc test. 
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Figure 12. Oxidative stress in the hippocampus of patients experiencing SE. 
Representative immunohistochemical micrographs of the CA1 region showing the expression of 
inducible nitric oxide (iNos; A-B), the cysteine transporter (Xct, C-D) and the transcriptional 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2; E-F) in control hippocampus (A,C,E) and in a 
patient who died after SE (7 weeks post-SE; B,D,F). Increased expression of these markers was 
observed in the hippocampus of patients post-SE in cells with neuronal (arrows in B,D,F and 
inserts) and glial morphology (arrowheads in B,D,F and inserts), as compared to controls. Nrf2 
expression shows nuclear expression (F), denoting an increase in the transcription of detoxifying 
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enzymes. Inserts in B show iNOS positive neurons (arrow in a, and co-localization with NeuN in 
b) and astrocytes (arrowhead in a, and co-localization with GFAP in c). Inserts in D show Xct  
positive neurons (arrow in a, and co-localization with NeuN in c) and astrocytes (arrowhead in b, 
and co-localization with GFAP in d). Inserts in F show NrF2 positive neurons (arrow in a, and co-
localization with NeuN in c) and astrocytes (arrowhead in b and co-localization with GFAP in d). 
Scale bar in F: A-F: 80µm; insert in B: 40µm; inserts in B,D,F: 25µm.     
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Fig. 13. Expression of HMGB1 in the hippocampus of patients with SE and in 
temporal lobe epilepsy with hippocampal sclerosis (HS). 
Representative immunohistochemical micrographs of HMGB1 signal in the CA1 region of 
control hippocampus (A) and the hippocampus of a patient who died after SE (7 weeks 
post-SE, B) and in epileptic patients (C), showing increased HMGB1 expression in post-
SE and HS specimens, as compared to controls, with cytoplasmatic staining in cells with 
neuronal (arrows in B, C and inserts a) and glial morphology (arrowheads in B, C and co-
localization with GFAP in inserts b). In control hippocampus (A), HMGB1 is exclusively 
localized in cell nuclei. Scale bar in: A-C: 80µm; inserts in B and C 25µm.  
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Fig. 14 Oxidative stress in the hippocampus of temporal lobe epilepsy patients with 
hippocampal sclerosis (HS). 
Representative Immunohistochemical micrographs of the CA1 region showing the expression of 
inducible nitric oxide (iNos; A, B), the cysteine transporter (Xct; C, D) and the transcriptional 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2; E-F) in control hippocampus (A, C, E) and in 
TLE-HS (B, D, F). In epileptic specimens, an increased expression of these markers was observed 
in cells with neuronal (arrows in B, D, F and inserts), and glial morphology (arrowheads in B, D, F 
and inserts), as compared to controls. In epileptic tissues, Nrf2 expression shows nuclear 
87 
 
expression (F), indicating increased transcriptional activation of detoxifying enzymes. Inserts in B 
show iNos-positive neurons (arrow in a, and co-localization with NeuN in b) and astrocytes 
(arrowheads in a, and co-localization with GFAP in c). Inserts in D show Xct-positive neurons 
(arrow in a, and co-localization with NeuN in b) and astrocytes (arrowhead in a, and co-
localization with GFAP in c). Inserts in F show Nrf2-positive neurons (arrow in a, and co-
localization with NeuN in c) and astrocytes (arrowheads in b, and co-localization with GFAP in d).  
Scale bar in F: A-F: 80µm; inserts in B, D, F: 25µm.  
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Figure 15. Experimental design of rats exposed to electrical status epilepticus (SE) 
and treatment schedule.  
Panel A refers to rats exposed to SE and used to test whether the combination of NAC and SFN 
was more effective in reducing oxidative stress than each drug given alone. Three different cohorts 
of SE-exposed rats were used, one cohort was treated with NAC (500 mg/kg, i.p., twice/day for 7 
days, panel a) or with SFN alone (5 mg/kg, i.p., once daily for 14 days, panel b), or with their 
combination (NAC+SFN for 7 days, then SFN alone for additional 7 days, panel c). Treatment 
began 60 min after SE onset. Rats were killed 14 days post-SE to assess oxidative stress markers 
in the hippocampus by HPLC. Data relate to Figure 5A. Panel B refers to rats treated for 4 days 
with NAC+SFN (doses as above), then killed for measurements of either oxidative stress markers 
by HPLC (Fig. 10A) or HMGB1 levels (Fig. 10B) in the hippocampus. Panel C refers to rats 
exposed to SE and used to study the therapeutic effects of the combined anti-oxidant drugs 
treatment (NAC+SFN for 7 days, then SFN alone for additional 7 days, see panel c). Treatment 
began 60 min after SE onset. Video-EEG recordings was done continuously from SE induction 
until the onset of the first two spontaneous seizures (epilepsy onset), and for 2 consecutive weeks 
(24/7) at 2 and 5 months post-SE. One h after SE induction, rats were randomized into treatment 
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(NAC+SFN) and vehicle groups (n=9 rats each group). At the end of EEG recording at 5 months 
post-SE, rats were tested in the T-maze, and then sacrificed for assessment of neuronal cell loss. 
Blood was withdrawn from the tail vein at the end of treatment (14 days post-SE) and at the time 
of rat sacrifice (5 months). Data relate to Figures 10 and 11. 
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CHAPTER III 
“NEW THERAPEUTIC STRATEGIES IN A MICE MODEL OF REFRACTORY 
STATUS EPILEPTICUS” 
 
3.1 INTRODUCTION 
3.1.1 Status Epilepticus: definition and classification 
Status Epilepticus (SE) is a condition resulting either from the failure of the mechanisms 
responsible for seizure termination or from the initiation of mechanisms, which lead to 
abnormally, prolonged seizures [1]. SE is a common life-threatening condition with a 
prevalence of 10-41/100,000 people [2,3]. Approximately 50% of these cases present with 
no prior diagnosis of epilepsy [4]. About 20% of patients will die as a result of SE [5].   
According the last classification of ILAE, SE can be defined by two operational 
dimensions: the first is the length of the seizure and the time point (t1) beyond which the 
seizure should be regarded as “continuous seizure activity.” The second time point (t2) is 
the time of ongoing seizure activity after which there is a risk of long-term consequences 
including neuronal death, neuronal injury, and alteration of neuronal networks, depending 
on the type and duration of seizures. In the case of convulsive (tonic–clonic) SE, the time 
points are 5 min for t1 and 30 min for t2, respectively and are based on animal 
experiments and clinical research [1]. 
From a taxonomical point of view, SE is a very heterogeneous condition; there are many 
forms of SE and causes prove to be extremely varied.  
SE can be classified following four diagnostic axes: semiology, etiology, EEG correlates 
and age.  In terms of semiology, the paramount dichotomous categorization occurs 
between forms with or without prominent motor signs, which are modulated, in parallel, 
by the occurrence of focal versus generalized clinical and electrographic features, as well 
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as by the degree of consciousness impairment [1]. 
Etiologies are classically divided into acute symptomatic, which account for over the half 
of all cases, remote symptomatic, progressive symptomatic and idiopathic/unknown [6]. 
The etiology of SE is also influenced by the age of onset (neonatal, infancy, childhood, 
adolescence/adulthood, elderly). 
In particular, while pediatric SE is more often caused by infections and genetic/congenital 
disorders [7], in adults antiepileptic drug (AED) withdrawal, cerebrovascular disorders 
and tumors predominate [7,8]. 
Focusing on inflammatory SE etiologies, CNS or severe systemic infections (viral, 
bacterial or parasitic) may account for 3–35% of cases, according to the geographical 
location: patients in developing countries are indeed more prone to have an infective 
etiology of SE [9,10]. Autoimmune etiologies globally seem rarer, accounting for only 
about 2–3% of SE episodes [9]. In patients with autoimmune SE, most of the episodes are 
related to anti-NMDA-receptor antibodies, anti-glutamic acid decarboxylase antibodies or 
multiple sclerosis, while other antibodies, including those associated with paraneoplastic 
syndromes, as well as Rasmussen encephalitis seem rarer [11]. SE episodes with 
potentially, yet unproven, inflammatory origin, often presenting in the context of a febrile 
illness without any previous history of seizures, account for about 5% of SE cohorts  [7,8]. 
In adults, such forms are called ‘new-onset refractory SE’ (NORSE) [12], while in 
children the acronym ‘febrile infection-related epilepsy syndrome’ (FIRES) has been 
proposed [13]. 
The exact incidence of these entities is still unclear, nevertheless, they may account for a 
significant proportion of super-refractory SE episodes. Finally, SE can be described 
according to the electroencephalographic patterns even if none of these ictal patterns is 
specific for any type of SE.  
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3.1.2 Treatment and Prognosis: 
Current standard of care includes three treatment lines: the first line agents represented by 
benzodiazepines (lorazepam, midazolam, clonazepam), second line agents by 
intravenously AEDs (levetiracetam, valproate, phenytoin) and third line agents by general 
anesthetics (Figure 1). 
 
 
Figure 1. Therapeutic management of Status epilepticus (from Vezzani et al, 2015) 
 
About one third of patients still continue seizing despite the first two treatment lines thus 
evolving to refractory SE, and half of these subsequently develop super-refractory SE, 
resistant to a first anesthetic treatment [14].  In these cases, alternative treatments as other 
anesthetics and AEDs, vagal nerve stimulation, ketogenic diet (KD), transcranial magnetic 
stimulation, electroconvulsive treatment, mild hypothermia or resective surgery can be 
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considered [14]. 
 Furthermore, refractory SE is linked to a worse prognosis, both in terms of mortality and 
morbidity. Decline in intellectual functions and cognitive deficits have been reported 
particularly in new onset refractory SE in both children and adults [13]. Moreover, chronic 
epilepsy development occurs in up to 50% of adults after de novo refractory SE [15,16]. 
AEDs have not shown a major impact on SE prognosis. Achieving control of SE without 
requiring prolonged drug-induced coma or severe EEG suppression correlate with better 
prognosis and improved functional outcome [17].  
SE in preclinical models is typically induced by a chemoconvulsant or electrical 
stimulation, mirroring de novo SE in humans [18]. Moreover, since experimental studies 
in multiple mammalian species demonstrated that SE itself is sufficient to induce 
neurological co-morbidities and epilepsy [19], the occurrence of prolonged unremitting 
seizures is likely to contribute to pathological outcomes in humans independently of 
underlying pathologies. This correlation between SE preclinical models and human 
pathology provides an ideal platform for developing new treatments that can move from 
pre-clinical testing to a clinical population with high unmet need.  
The search for potential therapeutic targets led to the identification of molecular 
mechanisms underlying SE development in rodents. In this context, endocannabinoid 
system and the proinflammatory arachidonic acid (AA)-derived eicosanoid cascade appear 
to play a significant role in the incidence of SE in animals, as well as for cell loss and co-
morbidities [20,21]. These two pathways are functionally linked in the brain by the 
activity of the key enzyme monoacylglycerol lipase (MAGL). 
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3.1.3 Role of MAGL pathway in epilepsy:  
MAGL is a serine hydrolase that preferentially hydrolyzes monoacylglycerols to glycerol 
and fatty acid, with highest expression in brain, white adipose tissue, and liver in mice and 
serves as a critical node for regulating these lipid signaling pathways in brain both in 
physiological and pathological conditions [22,23]. In brain, MAGL is expressed on 
presynaptic terminals and hydrolyzes the endocannabinoid 2-arachidoylglycerol (2-AG) 
into arachidonic acid (AA), the precursor for pro-inflammatory prostaglandin synthesis 
[24,25] 
                             
Figure 2. MAGL pathway in brain (modified from Mulvihill and Nomura, 2013) 
 
The endocannabinoid 2-AG is produced and released from postsynaptic neurons and then 
retrogradely binds presynaptic CB1 receptors, modulating presynaptic or interneuron 
release of excitatory or inhibitory neurotransmitters [26-28]. 
2-AG can also binds CB2 receptors on microglia cells [29], reducing neuronal firing 
frequency [30] and providing antinflammatory effects. 
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Prostaglandin E2 (PGE2) is the major product of COX-2 in the brain, and two of its 
receptors, EP1 and EP2, have been implicated in neuronal injury and inflammation in 
CNS disorders [31]. Pharmacological blockade of MAGL leads to an enhancement of 2-
AG signaling and a reduction of AA availability to COX-2, thus providing 
antinflammatory effect. The 2-AG has a crucial role for suppressing seizures in 
experimental model of epilepsy. In particular, in a kindling model of temporal lobe 
epilepsy, inhibition of MAGL by JZL184 provided a significant delay in the development 
of generalized seizures and a decrease in seizure thresholds. These effects were mediated 
by the action of 2-AG on CB1 receptors [32]. Moreover, kainite-induced seizures in mice 
lacking the 2-AG synthesizing enzyme were much more severe compared with those in 
CB1-receptor knock out mice and were comparable to those in mice lacking both cb1 and 
CB2 mediating signaling. This study confirmed the importance of 2-AG action on both 
CB1 and CB2 receptors [33].  
On the other hand, the inhibition of MAGL also decreases the levels of AA, needed for 
prostanoids synthesis. The antagonism of EP2 receptor has been shown to mediate 
neuroprotection and less neuroinflammation [34]. Moreover, the cognitive deficit 
developed after SE onset was prevented in rats treated briefly with the EP2 antagonist 
[34]. This suggests that much of the morbidity associated with COX-2 induction after SE 
is mediated by the activation of EP2, and possibly EP1, by COX-2 derived PGE2. Delayed 
inhibition of EP2 could therefore represent a viable adjunctive treatment for alleviating the 
deleterious consequences of SE.  
 
3.1.4 Role of ketogenic diet in epilepsy 
Ketogenic diet (KD) is a high-fat low-carbohydrate diet used as an effective treatment in 
patients with medically intractable epilepsy, including inflammation-induced epileptic 
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encephalopathies as FIRES [35].  
In clinical settings KD has been shown to stop refractory SE and improve cognitive deficit 
[36]; while in experimental models, KD prevents epileptogenesis and disease progression 
and provides significant neuroprotection [37]. At present, there are many hypotheses 
regarding KD effects, and it is becoming more apparent that the KD likely works through 
multiple mechanisms that target fundamental biochemical pathways linked to cellular 
substrates (e.g., ion channels) and mediators responsible for neuronal hyperexcitability.  
Among these several mechanisms, KD seems to provide anti-inflammatory effects. In 
particular, in a lipopolysaccharide (LPS)-induced fever model in rats KD reduces AA 
levels in blood and IL-1β in brain and blood, providing anti-inflammatory effects [38]. 
Moreover, KD or beta-hydroxybutirrate (BHB), one of the ketone bodies produced in liver 
during the diet, decreased caspase-1 activation and IL-1β secretion in mouse models of 
NLRP3-mediated diseases as familial cold autoinflammatory syndrome [39]. This anti-
inflammatory effect of the KD [40] may be due in part to BHB’s specific effects on the 
NLRP3 inflammasome, and further underscore the importance of inflammation in epilepsy 
[41]. 
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3.2 AIMS OF STUDY 
As status epilepticus is a commonly drug-refractory condition, novel therapies are greatly 
needed to rapidly terminate ongoing seizures for preventing mortality and morbidity.  
In this study, we investigated if MAGL inhibition using the brain penetrant selective and 
irreversible inhibitor CPD-4645, affects diazepam-refractory SE in mice, and reduces 
pathological sequelae such as cognitive deficits and cell loss. 
To further characterize the mechanism of action, we investigated whether CPD-4645 
effects were mediated by a reduction of excitatory synaptic transmission due to 2-AG 
modulation of CB1 receptors or by reduction of AA availability for the eicosanoid cascade 
and 2-AG activation of microglial CB2 receptors, thereby inducing antinflammatory 
effects.  
Finally, we studied the effect of MAGL inhibition on SE in mice fed with a ketogenic diet 
(KD) for assessing a potential synergy between these two treatments since the KD is one 
therapeutic option for controlling refractory SE in humans.  
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3.3.5 Mouse model of status epilepticus 
 Mice were surgically implanted under general gas anesthesia (1-3% isoflurane in O2) and 
stereotaxic guidance. A 23-gauge guide cannula was unilaterally positioned on top of the 
dura mater for the intra-amygdala injection of kainic acid (from bregma, mm: nose bar 0; 
anteroposterior-1.06, lateral -2.75) [44]. In mice a nichrome-insulated bipolar depth 
electrode (60 µm OD) was implanted in the dorsal hippocampus (from bregma, mm: nose 
bar 0; anteroposterior –1.8, lateral 1.5 and 2.0 below dura mater) [44] ipsilateral to the 
injected amygdala and a cortical electrode was placed onto the somatosensory cortex in 
the contralateral hemisphere.  
Kainic acid (KA) (0.3 μg in 0.2 μl) was injected in the basolateral amygdala in freely 
moving mice (n=70) using a needle protruding of 3.9 mm below the implanted cannula. 
Status epilepticus (SE) developed after approximately 10 min from KA injection, and was 
defined by the appearance of continuous spikes with a frequency >1.0 Hz. Spikes were 
defined as sharp waves with an amplitude at least 2.5-fold higher than the baseline and a 
duration of <20 msec, or as a spike-and-wave with a duration of <200 msec. The end of 
SE was determined by inter-spike interval >2 sec. After 40 min from SE onset, mice 
received a sedative dose of diazepam (10 mg/kg, i.p.) for decreasing motor seizures and 
improving mice survival. However, electrographic SE was unaltered by diazepam. Power 
spectral density (PSD) distribution of five frequency bands (delta: 1–4 Hz; theta: 4–8 Hz; 
alpha: 8–13 Hz; beta: 13-30 Hz; gamma: 30–40 Hz) was calculated during the first 4 h of 
SE. Fast Fourier transforms (FFTs) were computed by 50% overlapping sliding windows 
(1.024 data-point each) with Hanning windowing function. EEG data were normalized by 
dividing the EEG power density at each frequency with the EEG power density averaged 
across all frequencies. SE was successfully evoked in 65 out of 70 mice, of which 10 mice 
died, therefore 55 mice were used for the experiments. The total number of spikes was 
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measured during 12 h after KA administration (Clampfit 9.0, Axon Instruments, Union 
City, CA, U.S.A). The effect of CPD-4645 vs its vehicle was tested in 32 mice fed with a 
standard diet and 23 mice fed for 4 weeks with a ketogenic diet (KD; #F3666, Bio-serv, 
Frenchtown, NJ, USA). At the end of SE, mice were tested in a spatial memory task, in 
particular Novel Object recognition test and, then, they were killed for histological 
analysis of cell loss. At the time of killing, blood was withdrawn from heart atrium and 
serum separated and aliquoted for analysis of beta-hydroxybutyrate. Two additional 
experimental groups consisted of mice undergoing the same surgical procedure as 
described above and fed either with standard (n=12) or KD (n=7). These mice were used 
as sham controls (not exposed to SE) in the novel object recognition test and for 
histological analysis.  
Cnr1
-
/
- 
mice: Cnr1
-
/
-
 mice (n=18) and their respective WT littermate controls (n=16) 
underwent the same protocol of status epilepticus, described above. SE was successfully 
evoked in 28 out of 34 mice and these animals were used for the experiments.   
 
3.3.6 CPD-4645 treatment 
Mice were fed ad libitum with standard diet (SD) or ketogenic diet (KD) for 4 weeks in 
order to induce ketosis. A cohort of randomized mice in each diet group (SD or KD) 
received intraamygdala KA injection and 1 h after SE onset, animals were randomized to 
either CPD-4645 [10 mg/kg, i.p., dissolved in DMSO:cremophor:saline (0.5% 
DMSO:0.5% cremophor)] or vehicle injection. A second injection of either drug or 
vehicle was done in the same mice 7 h post-SE onset to maintain therapeutic drug levels 
as indicated by PK analysis, and then mice were treated twice a day for the following 
week until completion of behavioral test.  
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Cnr1
-
/
- 
mice: Cnr1
-
/
-
 and Wt mice were fed ad libitum with standard diet. They were 
randomized to either CPD-4645 [10 mg/kg, i.p., dissolved in DMSO:cremophor:saline 
(0.5% DMSO:0.5% cremophor)] or vehicle injection.  For this experimental group, we 
followed the same treatment schedule described above.    
 
3.3.7 Novel object recognition test (NORT)  
All experiments began between 9:00 and 10:00 am. Two days after the end of SE, spatial 
memory was tested in mice in NORT where the ability of rodents to recognize a set of 
novel objects in an otherwise familiar environment is taken as a measure of recognition 
memory [45]. Although this task is associated with the perirhinal cortex function, we used 
a 24 h intertrial interval from familiarization to test phase, a condition which also involves 
hippocampal activity [46, 47]. The test was performed in the open-square gray arena (40 x 
40cm) surrounded by 30 cm high wall, with the floor divided into 25 equal squares by 
black lines. Mouse behavior was remotely monitored via video camera. Twenty four hours 
prior to the test, mice were allowed to habituate in the arena for 5 min. The proper test 
began on the next day with the familiarization phase, when mice were placed into the open 
field for 10 min in the presence of two identical objects positioned in internal non-adjacent 
squares. The following objects were randomly used: black plastic cylinders (4 x 5 cm); 
transparent scintillation vials with white caps (3 x 6 cm); metal cubes (3 x 5 cm); plastic 
black pyramids (4 x 5 cm). Cumulative exploration time of both objects and of each object 
separately was recorded. Exploration was defined as sniffing, touching, and stretching the 
head toward the object at a distance not more than 2 cm. Twenty four hours after 
familiarization, the recognition phase of the test was performed: mice were placed for 10 
min in the open field, which contained one object presented during the familiarization 
115 
 
phase (familiar object, F), and a novel unfamiliar object (N). The time spent exploring N 
versus F represents a measure of trial unique recognition memory. As the recognition 
phase was performed 24 h after the familiarization phase, the procedure can be regarded as 
a test of long-term memory. Time spent (s) exploring F and N was expressed as a 
discrimination index: (N - F)/(N + F).  
 
3.3.8 Fluoro-Jade staining  
At the end of behavioural tests, mice were deeply anaesthetized using 10% ketamine+ 
10% medetomidine + 80% saline; 10 ml/kg, i.p.) then perfused by the ascending aorta 
with cold PBS (50 mM, pH 7.4). After decapitation, brains were rapidly removed and the 
hemisphere ipsilateral to KA injection was post-fixed in 4% paraformaldehyde (PAF) 
solution at 4°C for one week, then transferred to 20% sucrose in PBS for 24 h at 4°C. 
Tissue was rapidly frozen in -50°C isopentane for 3 min and stored at -80°C until assayed. 
Serial cryostat coronal sections (40 µm) were cut throughout the septal extension of the 
hippocampus (−1.22 to −2.54 mm from bregma) [44] and slices were collected in 0.1 M 
PBS. Four sections for each animal were stained with Fluoro-Jade to detect degenerating 
neurons [48,49]. Sections from control and experimental mice were matched for antero-
posterior location. High-power non-overlapping fields of the whole hippocampus (20X 
magnification; Olympus) were acquired to measure the Fluoro-Jade-stained neurons along 
the CA1, CA3, CA4 pyramidal cell layers and amygdala. Data obtained in each image 
within the same hippocampal subfield were added together providing one single value per 
slice in each mouse. Data obtained in each of the 4 slices per brain were averaged, 
providing a single value for each brain, and this value was used for statistical analysis.   
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3.3.9 Real-time quantitative polymerase chain reaction analysis 
The contralateral hemisphere in each brain was snap frozen and kept for mRNA isolation 
and qRT-PCR analysis.  Total RNA was isolated from frozen tissues using Qiazol lysis 
reagent and RNeasy columns following manufacturer directions. cDNA was synthesized 
using high capacity RNA to cDNA master mix (Applied Biosystems). Reactions for 
quantitative TaqMan PCR contained 1x primer/probe sets, cDNA and gene expression 
master mix in a 10 uL final volume (Applied Biosystems). PCR was performed for 40 
cycles using a Viia 7 machine. Relative quantitation (2^-ΔΔCT) of gene expression was 
determined using β-actin (Actb) as the endogenous control gene. Primer probe sets were 
purchased from Applied Biosystems [Il1β: Mm01336189_m1; Ptgs2: MmXXXXX_m1; 
Mgll: Mm00449274_m1].   
 
3.3.10 β-hydroxybutyrate measurement in plasma  
Blood was collected for mice at indicated timepoints post dosing via cardiac puncture into 
K2-EDTA vacutainers and kept on ice. Plasma was isolated by centrifugation at 4,000 rcf 
for 5 minutes. β-hydroxybutyrate was measured using a colorimetric assay kit (Cayman 
Chemical, No700190). Kit was performed according to manufacturers directions at a 
sample dilution of 1:5.  
 
3.3.11 Randomization and statistical analysis of data  
Sample size was a priori determined based on previous experience with the animal model 
and the respective behavioral analyses. Simple randomization was applied to assign a 
subject to a specific experimental group (vehicle or drug) using a web site randomization 
program (http://www.randomization.com). After vehicle or drug injection, rats were 
linked to numerical identifiers by an external investigator not involved in the study and  
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3.4.2 Effect of CPD-4645 on status epilepticus and the associated cognitive deficit in 
standard diet (SD)-fed mice  
The MAGL inhibitor CPD-4645 blunted the development of SE in mice fed with a 
standard diet. In vehicle-injected mice, spiking activity increased in frequency during the 
first 3 h from SE onset reaching a plateau between 4 h and 7 h, then spike frequency 
progressively declined until SE spontaneously elapsed (Fig.4A, n=21). CPD-4645 reduced 
spike frequency by 60% on average starting from 3 h after drug injection as compared to 
spike frequency in time matched vehicle-injected mice (p<0.01; n=21) (Fig.4A,B).  
The drug significantly reduced the alpha band frequency (8–13 Hz; p<0.01; n=6) during 
the first 3 h from injection vs vehicle (n=5) as assessed by Power Spectral Density (PSD) 
analysis (Figure 4A, inset). No significant differences of PSD (µV2/Hz) for the delta: 1–4 
Hz (SE+Vehicle 9.06 ± 0.7; SE+drug 11.06 ± 0.6); theta: 4–8 Hz (SE+Vehicle 4 ± 0.4; 
SE+drug 3.6±0.3); beta: 13-30 Hz  (SE+Vehicle 0.52 ± 0.03; SE+drug 0.4 ± 0.01); 
gamma: 30–40 Hz (SE+Vehicle 0.05 ± 0.005; SE+drug 0.04 ± 0.002) bands were found. 
Total duration of SE was 9.2 ± 0.4 h in vehicle-injected mice which was shortened by 4 h 
in drug-treated mice (4.9 h ± 0.5, p<0.05) (Fig.4B).  
To determine whether CPD-4645 rescues impaired memory following SE, we compared 
NORT performance among five experimental cohorts of mice as follows: 1) naïve mice; 
2) sham mice injected with vehicle, 3) sham mice injected with CPD-4645; 4) SE-exposed 
mice injected with vehicle; 5) SE exposed mice injected with CPD-4645. Naïve (n=14) 
and sham mice, treated either with vehicle (n=13) or drug (n=8), spent more time 
exploring the novel object compared to the familiar one (average discrimination index= 
0.37± 0.05;  0.4 ± 0.05 and 0.28 ± 0.03 respectively), indicating that they remembered the 
familiar object from the object familiarization phase and thus had a preference for the 
novel object (Fig. 4C). 
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SE-exposed mice injected with vehicle (n=10) failed to remember the familiar object and 
spend more time exploring this object as the novel one (average discrimination index = 
 -0.24 ± 0.07; p<0.001 vs naïve; p<0.001 vs drug-injected sham mice; p<0.05 vs drug-
injected sham mice) (Fig.4C). 
CPD-4645 rescued this behavioral deficit as shown by the average discrimination index of 
0.28± 0.05 (p<0.05 vs vehicle-injected SE-exposed mice) which is similar to naïve and 
sham mice. No difference in locomotor activity was detected among the experimental 
groups in the first day of NORT. Mice did not show behavioral seizures during the test. 
 
3.4.3 Effect of CPD-4645 on status epilepticus in Cnr1
-
/
- 
and related
 
Wt mice and 
survival curves 
In order to better characterize the mechanisms of CPD-4645 effects on SE, the same 
treatment protocol was applied in Cnr1-/- and related Wt mice. The drug significantly 
decreased the number of spikes as compared to vehicle in Cnr1
-
/
- 
mice (n=7/group; 
p=0,005, two-way ANOVA, F 8.082 between 1 and 144 degrees of freedom), starting 
from 3 h after drug injection (Fig.5A,B). Total duration of SE was significantly shortened 
by 4 h in drug-treated mice (6.4 ± 1.3 h) as compared to control mice (10± 0.5 h; p<0.05). 
As far as Cnr1
-
/
- 
 sensitivity to SE, Cnr1
-
/
-  
mice developed a more severe SE in terms of 
spike number as compared to respective
 
 Wt mice (Fig.5A,4A). The drug confirmed its 
therapeutic effects on SE also in Cnr1Wt related mice (Fig. 5A,B). 
Cnr1
-
/
-  
mice showed a higher mortality rate during the days after SE onset as compared to 
Wt controls (p< 0.05 by Kaplan–Meier survival analysis). This mortality rate was 
unaffected by the drug in each strain, therefore all data were put together independently on 
vehicle or drug treatment  (Fig.6C). 
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3.4.4 MAGL inhibition attenuates neuroinflammation following SE 
To assess the expression of inflammatory mediators in the brain following SE, the 
contralateral hippocampus of SE-exposed mice was harvested (the ipsilateral hippocampus 
was used for 2-AG measurement at 1 h while the whole ispilateral hemisphere was used 
for Fluoro-Jade analysis of cell loss at 7 days) at 1 h and 7 days after CPD-4645 or vehicle 
injection. IL-1β (Il-1b) and COX-2 (Ptgs2) transcripts were induced by 4.3 ± 0.8- and 8.4 
± 2.4-fold respectively following SE and this effect was progressively reduced by CPD-
4645 (p<0.05 at 7 days; Figure 4). MAGL expression (Mgll) was unaltered by SE or drug 
treatment which is consistent with MAGL being a constitutive (non-inducible) enzyme. 
 
3.4.5 Effect of CPD-4645 on status epilepticus in ketogenic diet (KD)-fed mice 
In vehicle-injected mice fed with KD (n=12), spiking activity pattern, frequency of spikes 
and SE duration were similar to standard diet-fed mice, except for the first hour after SE. 
However, when CPD-4645 was injected in KD-fed mice (n=11), SE was virtually 
abrogated and the drug’s effect was immediate, starting  at 1 h from injection (Fig.8A). 
Total duration of SE was significantly reduced by 7 h in drug-treated (3.4 h ± 0.7 h) as 
compared to vehicle-injected mice (10.0 ± 1.0 h) (p<0.01) (Fig.8B). 
All mice fed with KD, regardless of treatment with CPD-4645, showed high levels of β-
hydroxybutyrate in plasma as compared to mice fed with SD, confirming they were in 
ketosis  (Fig.9). 
 
3.4.6 Effect of CPD-46454 on neuronal cell loss 
At the end of behavioral testing, mice were killed for quantitative analysis of cell loss in 
Fluoro-jade sections of the dorsal hippocampus and amygdala, ipsilateral to the KA 
injection. In CPD-4645 treated SD-fed mice, CA1 pyramidal cell loss was significantly 
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reduced (number of FJ-positive cells/slice, 1.8 ± 1.2, n=8) compared to vehicle-injected 
mice (199.8 ± 43.0, n=12) (Fig.10A). CPD-46454 did not afford neuroprotection in the 
hilus while a 34% decrease in cell loss was found in CA3/CA4 (SE+Vehicle, 52.8 ± 10.5; 
SE+CPD-4645, 34.8 ± 7.7) (Fig.10A). The KD itself greatly reduced the number of 
Fluoro-Jade-positive CA1 pyramidal neurons in SE-exposed mice (0.75 ± 0.5; Fig.10B). 
In CPD-4645 treated KD-fed mice, virtually no cell loss was observed in CA1 while 
degenerating neurons in the amygdala were reduced by half vs vehicle-injected mice 
independently on the diet (Fig.10B). A 33% reduction was observed in CA3/4 
(SE+Vehicle, 33.8 ±17.0; SE+CPD-4645, 22.8 ± 11.0) although this difference was not 
statistically significant. 
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3.5 DISCUSSION 
Studies in several animal models demonstrate that SE induced either by chemoconvulsant 
drugs or electrical stimulation causes a rapid and intense inflammatory cascade in the 
forebrain involving interactions among neurons, reactive astrocytes, activated microglia, 
vascular endothelial cells and infiltrating monocytes from  the blood  [50]. 
Prostaglandins produced by cyclooxygenase 1 and 2 (COX-1/2) [51] expressed in neurons 
and glial cells [52] play an important role in inflammatory cascade generated in the brain 
during SE. Experimental studies demonstrated that rodents treated with COX-1/2 
inhibitors or knock-out (KO) mice for these enzymes show neuroprotection in models of 
neurodegenerative disorders with a neuroinflammatory component such as Parkinson's and 
Alzheimer's [53, 54] and also in status epilepticus models [55]. 
MAGL is a constitutively active enzyme and is mainly expressed in the hippocampus, 
amygdala, cerebellum and prefrontal cortex [56] and plays a crucial role in the synthesis 
of prostanoids [57].  
Recent experimental studies showed that genetic or pharmacological inactivation of 
MAGL causes a significant reduction in AA levels in the brain and a consecutive increase 
of 2-AG pool that selectively acts on CB1 or CB2 receptors, providing antiexcitatory and 
antiinflammatory effects [58-60]. Interestingly, the 2-AG can suppress seizures and 
provides anti-epileptogenic effects by reducing excitatory synaptic inputs in the dentate 
gyrus through CB1 and CB2 receptors [32,33].  
Our data confirmed that MAGL inhibition mediated by CPD-4645 increases the levels of 
2-AG and reduces the biosynthesis of AA, essential for prostanoids synthesis (Fig.3). 
However,  treatments targeting the pathway of AA and prostaglandins (i.e. EP2 receptor 
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antagonists) provided neuroprotection, reduced inflammation and SE-related mortality, 
but failed to interfere with SE [34, 61]. 
Notably, CPD-4645 is the first “anti-inflammatory” treatment able to dramatically reduce 
the development of SE in animals resistant to diazepam, which is one of the first line 
agents for SE in clinical practice. The drug administration time (i.e. 60 min) after SE onset 
is also compatible with the proposed treatment algorithm for novel interventions for 
human refractory SE ( i.e., there is no clear evidence to guide therapy after 40-60 min 
phase of unremitting SE) [62]. 
Moreover, MAGL inhibition rescues the cognitive deficit in NORT (Fig.4), confirming 
recent data of Dingledine et al. which demonstrated that EP2 antagonism blocks long term 
memory impairment in rats expiriencing organophosphorus-induced SE [63]. 
Interestingly, CPD-4645 also affords neuroprotection in the hippocampal CA1 subregion 
and amygdala, ipsilateral to KA injection (Fig.10). The neuroprotective effects in CA1 are 
also provided by KD itself, confirming experimental studies in which ketone bodies, 
especially β-hydroxybutyrate conferred neuroprotection against different types of cellular 
injury [64]. 
Thus, MAGL inhibition may mediate therapeutic effects on SE and related pathological 
consequences  by two main mechanisms: 1. accumulation of 2-AG which activates the 
presynaptic CB1R, thereby reducing glutamate-mediated excitatory neurotransmission 
[60]; 2. antiinflammatory effects resulting from lowering of AA and reduction of 
eicosanoids synthesis as well as 2-AG mediated activation of CB2 receptors expressed by 
activated glial cells, thereby reducing their pro-inflammatory phenotype [65,66]. 
Our findings support that MAGL inhibition reduces SE mainly via an antiinflammatory 
mode of action since its therapeutic effect was unaltered in the absence of CB1R. 
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The CB2-mediated antinflammatory action is also supported by the reduction of 
proinflammatory cytokines, in particular IL-1β and COX-2,  in the hippocampus of CPD-
4645-treated  mice (Fig.7).  
Infact, the IL-1β- IL-1 receptor type 1 axis and the PGE2 activating EP1 receptors play a 
key role in the pathological sequaele related to SE (i.e cognitive deficits, neuronal cell 
loss) [34,62,67]. 
The abrogation of SE in a short time is critical for reducing mortality and preventing the 
long-term pathological consequences in clinical settings (including neuronal injury, 
neuronal death, functional deficits)[1].  
Despite the maximal MAGL inhibition occurs within 30 minutes from drug injection, as 
indicated by the pharmacokinetic and pharmacodynamic data, the CPD-4645 maximum 
effect on SE occurs from the 3
rd
 hour after injection.  The delayed therapeutic effect of 
CPD-4645 may depend on the availability of a pre-existing pool of AA for 
proinflammatory eicosanoid synthesis. The anticipation of the drug effects on SE in KD-
fed mice may be due to the reduction of this pool of AA as suggested by evidence from  
literature [38]. Moreover, KD is also able to decrease inflammatory mediators as IL-1β in 
brain and blood, providing anti-inflammatory effects [38]. The diet's anti-inflammatory 
effect can be mediated by dietary polyunsaturated fatty acids (PUFAs): in particular, N-3 
PUFAs can decrease the production of inflammatory eicosanoids, cytokines, and reactive 
oxygen species. They can inhibit the Nuclear Factor Kappa B-mediated transcriptional 
activation of inflammatory genes by activating peroxisome proliferator-activated receptors 
or exert anti-inflammatory actions by promoting the generation of resolvins and 
docosanoids [68,69]. 
Notably, beta-hydroxybutyrate decreased caspase-1 activation and IL-1β secretion through 
specific effects on the NLRP3 inflammasome  [39,40]. 
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Thus, we demonstrate for the first time that the antinflammatory effects of MAGL 
pharmacological  blockade are potentiated by KD and the combination of these two 
treatments is able to block SE.  
Our results suggest that MAGL may be a promising therapeutic target for refractory SE 
and for preventing the associated pathological long term consequences.  
Searching for a clinical translation of these results, MAGL inhibitor might represent a new 
interesting drug to stop benzodiazepine-resistant SE arising in patients with severe 
immune-mediated pharmacoresistant epileptic encephalopathies (i.e. FIRES) already 
treated with KD.   
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CONCLUSIVE REMARKS 
 
To date, targeting pharmacoresistant epilepsies represents an unmet clinical need in the 
field of experimental and clinical research on epilepsy. The next generation of therapies 
for epilepsy needs to target the mechanisms intimately involved in the process of 
epileptogenesis to allow the development of preventive or disease modifying treatments. 
The identification of the optimal time window for intervention is crucial for therapeutic 
success. One critical step is to move from proof-of-concept anti-epileptogenesis studies in 
animal models to validation in preclinical trials, and eventually to clinical translation. 
In fact, anti-epileptogenesis or disease-modifying therapies for preventing or delaying the 
onset of the epilepsy are still missing in clinical setting. 
In this PhD thesis, I pointed my attention on the role of neuroinflammation in the 
mechanisms of epileptogenesis. Specific inflammatory molecules and pathways have been 
shown to significantly contribute to the mechanisms of seizure generation and progression 
in different experimental models. 
In particular, I have contributed to demonstrate for the first time that targeting oxidative 
stress with clinically tested drugs for a limited time window post-injury significantly 
delayed the onset of epilepsy, blocked disease progression and drastically reduced 
spontaneous seizures and long-term pathological consequences (cell loss, cognitive 
deficit). This intervention may be considered for patients exposed to potential 
epileptogenic insults as status epilepticus. Drug-induced reduction of oxidative stress 
prevented disulfide HMGB1 generation, thus highlighting a potential novel mechanism 
contributing to therapeutic effects. 
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Moreover, my research work provided evidence supporting that monoacylglycerol lipase 
(MAGL) is a new potential target for drug development in epilepsy, in particular for the 
treatment of drug-refractory status epilepticus (SE). Inhibition of MAGL by a new potent 
and selective irreversible inhibitor (CPD-4645) protects mice against refractory SE and its 
therapeutic effects are potentiated by the ketogenic diet. 
In conclusion, all these experimental data contribute to better clarify the complex 
mechanisms underlying the pathophysiology of epilepsy, in order to identify new potential 
therapeutic targets. However, the major challenge will be represented by the translation of 
these experimental  results  into clinically effective human  therapies.  
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